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ABSTRACT 
Cytochrome P450 enzymes (CYPs) are responsible for the metabolism of the majority 
of therapeutic drugs. This thesis focuses on one of the CYP subfamilies, CYP2C, 
especially CYP2C9 and CYP2C19, which are responsible for the metabolism of 15–
20% of all drugs. All CYP2C enzymes are polymorphic, i.e. there are genetic variants, 
which have functional consequences for drug metabolism. Individuals can be classified 
according to their CYP2C metabolic capacity in extensive (EMs), intermediate (IMs) 
and poor metabolisers (PMs). Recently, a novel variant of the CYP2C19 gene was 
described in individuals with high metabolic capacity. This allele, CYP2C19*17, has 
been claimed to cause ultrarapid metabolism (UM) of CYP2C19 substrates. 
The aim of this thesis is to explore some of the aspects underlying varying metabolic 
capacity between, and within, individuals with the focus on genetics and drug–drug 
interactions. The thesis is based on five published papers. 
In Paper I we explored the influence of the genetic variant CYP2C9*3 on the CYP2C9 
dependent metabolism of the anti-inflammatory and analgesic drug celecoxib. We 
found a seven-fold higher median exposure at steady-state in homozygous carriers of 
the CYP2C9*3 allele compared to homozygous wild-type subjects. This might be one 
factor behind the increased risk of cardiovascular events that has been observed in 
long-term users of celecoxib in a dose-dependent fashion. 
Paper II and III focused on the CYP2C19*17 allele that has been associated with 
extensive metabolism of CYP2C19 substrates. We showed a 52% lower exposure of 
omeprazole in homozygous *17 carriers compared to homozygous wild-type subjects 
after a single dose of 40 mg. Regarding steady-state levels of escitalopram (5 mg twice 
daily for a week), we noted a trend towards a 21% lower exposure in CYP2C19*17 
homozygous individuals. However, this did not reach statistical significance in this 
study that was powered for a 40% difference. The clinical impact (or lack of impact) of 
this allele for various clinically important CYP2C19 substrates will be discussed in the 
thesis. 
A clinical consultation was the starting point for Paper IV in which we described eight 
cases of increased anticoagulant effect of warfarin in connection with concomitant use 
of noscapine; a cough medicine available over-the-counter. These cases were reported 
to the Swedish adverse drug reactions (ADR) register and we could show that they 
yielded a statistically significant signal worthy of further investigation. In vitro 
experiments were performed, showing that noscapine strongly inhibited CYP2C9 and 
CYP3A4, the key enzymes in warfarin metabolism. 
Besides noscapine, another OTC drug, glucosamine, has attracted interest for suspected 
interaction with warfarin. In Paper V we addressed the pharmacokinetic aspect of these 
interactions by giving a cocktail of four probe drugs before and during noscapine or 
glucosamine. Compared to baseline phenotyping, significant inhibition of both 
CYP2C9 (4.9-fold increase in the urinary losartan/E3174 ratio; 95% CI 2.8 - 8.4) and 
CYP2C19 (3.6-fold increase in the plasma omeprazole/5-hydroxyomeprazole ratio; 
95% CI 2.6 - 4.8) was seen during noscapine treatment. This is likely to explain the 
observed interaction with warfarin. No enzyme inhibition was seen with glucosamine 
and a metabolic interaction between warfarin and glucosamine seems highly unlikely. 
  
SAMMANFATTNING 
De flesta läkemedel behöver omvandlas till mer vattenlösliga substanser för att kunna 
utsöndras ur kroppen. Denna metabolism sker i många fall av enzymer tillhörande 
superfamiljen cytokrom P450 (CYP). Denna avhandling fokuserar på en underfamilj av 
cytokrom P450, nämligen CYP2C, särskilt de två enzymerna CYP2C9 och CYP2C19, 
som är ansvariga för metabolismen av 15-20 % av de kliniskt mest använda läke-
medlen. Alla CYP2C-enzymer är polymorfa, d.v.s. det finns genetiska varianter som 
har funktionella konsekvenser för nedbrytningen av läkemedel. Utifrån sin förmåga att 
omvandla CYP2C-substrat kan individer klassas som snabba (extensive metabolisers, 
EM) eller långsamma metaboliserare (poor metabolisers, PM). Nyligen beskrevs en ny 
variant av CYP2C19-genen hos individer med hög metabol förmåga. Denna genetiska 
variant (CYP2C19*17) har hävdats orsaka ultrasnabb metabolism (UM) av läkemedel 
som omsätts via CYP2C19. 
Målet med denna avhandling är att undersöka några av de faktorer som orsakar att för-
mågan att omsätta läkemedel varierar mellan och inom individer. Särskilt fokus ligger 
vid genetiska aspekter och läkemedelsinteraktioner. Avhandlingen bygger på fem 
publicerade delarbeten. 
I delarbete I undersöktes betydelsen av den genetiska varianten CYP2C9*3 för för-
mågan att bryta ned det inflammationshämmande och smärtstillande medlet celecoxib. 
Vi fann en sjufaldigt högre medianexponering för celecoxib hos individer med dubbel 
uppsättning av CYP2C9*3 jämfört med individer med två normala CYP2C9-gener. 
Detta kan vara en av de faktorer som ligger bakom den dosberoende ökning i risken att 
drabbas av hjärt-kärlhändelser som observerats hos långtidsanvändare av celecoxib. 
Delarbete II och III fokuserade på den genetiska varianten CYP2C19*17 som för-
knippats med snabb omsättning av läkemedel som bryts ned via CYP2C19. Efter en 
enkeldos av magsårsmedicinen omeprazol (40 mg) uppvisade försökspersoner med 
dubbel uppsättning av CYP2C19*17 i genomsnitt 52 % lägre exponering för omeprazol 
jämfört med individer med den vanliga varianten av CYP2C19-genen. Efter upprepad 
dosering av det antidepressiva läkemedlet escitalopram (5 mg två gånger dagligen i en 
vecka) noterades genomsnittligt 21 % lägre exponering hos försökspersoner med två 
kopior av CYP2C19*17, men denna skillnad var inte statistiskt säkerställd eftersom 
studien var dimensionerad för att påvisa en skillnad om 40 % mellan grupperna.  
En klinisk frågeställning var utgångspunkten för delarbete IV, i vilket vi beskrev åtta 
fall med ökad effekt av det blodförtunnande läkemedlet warfarin vid samtidig medici-
nering med noskapin; en receptfri hostmedicin. Provrörsförsök visade att noskapin var 
en stark hämmare av både CYP2C9 och CYP3A4, två av de viktigaste enzymerna för 
nedbrytningen av warfarin. 
Ett annat receptfritt läkemedel, glukosamin (som används mot ledbesvär), har miss-
tänkts kunna interagera med, och förstärka effekten av, warfarin. För att undersöka om 
dessa misstänkta läkemedelsinteraktioner berodde på hämmad metabolism av andra 
läkemedel gavs i delarbete V en cocktail av fyra olika markörläkemedel före och under 
behandling med noskapin eller glukosamin. Under behandling med noskapin sågs en 
påtaglig hämning av både CYP2C9 och CYP2C19. Detta förklarar sannolikt den obser-
verade interaktionen med warfarin. Under glukosaminbehandling noterades ingen 
enzymhämning och en metabol interaktion mellan warfarin och glukosamin förefaller 
således osannolik. 
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1 INTRODUCTION 
1.1 THE QUESTION 
On Valentine’s Day 2006, E., an 82-year-old retired physician with recurrent respira-
tory infections, once again got a bad cough. He was prescribed the OTC* cough syrup 
Nipaxon in a normal dose equivalent to 150 mg noscapine daily. E. had suffered a 
stroke two years earlier and had paroxysmal atrial fibrillation. Hence, he was treated 
with the anticoagulant† warfarin in a weekly dose of 20–20.5 mg. His INR‡ had been 
stable within the therapeutic range. However, after six days of concomitant noscapine 
treatment, E.’s INR was 7.2, i.e. he was at great risk of bleeding. The same day his 
doctor called the Drug Information Centre at the Karolinska University Hospital and 
asked the question “Is noscapine known to interact with warfarin?” The answer to this 
question was “no”, but in science it all depends on how you put the question. By asking 
the right question, the limits of knowledge can be extended. “Does noscapine interact 
with warfarin?” was the question that made this thesis become a unity and Papers IV 
and V are parts of the answer. First, however, a few other things need to be clarified. 
 
1.2 CLINICAL PHARMACOLOGY 
1.2.1 Introduction 
The field of Clinical Pharmacology is about the safe and rational use of therapeutic 
drugs. To be able to prescribe and use therapeutic drugs safely and rationally, one has 
to know something about pharmacokinetics§ (what the body does to the drug) and 
pharmacodynamics** (what the drug does to the body). These are the basics for all other 
branches of clinical pharmacology, including therapeutic drug monitoring (TDM), 
pharmacoepidemiology (the science of therapeutic drug use in the community), 
pharmacovigilance††, drug interactions, clinical trials, and drug development. The 
following subsections on pharmacokinetics and pharmacodynamics are, unless 
otherwise stated, freely based on text books in pharmacology and clinical pharmaco-
logy, such as Rang & Dale, Rowland & Tozer, and Gabrielsson & Weiner [1-3]. 
 
                                                 
*
 OTC is an abbreviation of over-the-counter, i.e. available without a doctor’s prescription 
†
 Anticoagulant, from Greek anti- (against) and Latin coagulare (to clot), refers to a substance that 
prevents the blood from clotting 
‡
 INR (International Normalized Ratio) is a measure of anticoagulant effect. Normal INR is 1.0, 
therapeutic INR is 2.0–3.0. 
§
 Pharmacokinetics (PK), from Greek phármakon (drug) and kīnētikós (moving), the branch of 
pharmacology concerned with the way drugs are taken into, move around, and are eliminated from, the 
body. 
**
 Pharmacodynamics (PD), from Greek dynamikós (relating to the force), the branch of pharmacology 
dealing with the action and effect of drugs. 
††
 Pharmacovigilance, from Greek phármakon (drug) and French vigilance (attentiveness), the science 
and activities relating to the detection, assessment, understanding and prevention of adverse effects or any 
other drug-related problem. 
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1.2.2 Pharmacokinetics 
1.2.2.1 ADME 
Drugs that are given orally need to be absorbed (A) in the gut to reach the systemic 
circulation for further distribution (D) to the site of action before being metabolised (M) 
and excreted (E). Absorption can be by passive diffusion or by active transport. Many 
drugs are even actively extruded back into the gut lumen once taken up into the epi-
thelial* cells of the gut wall. The blood from the gut passes the liver before being 
distributed to the rest of the body. Absorption and distribution often involves active 
transport (in or out) through the gut wall, blood–brain barrier, blood–placenta barrier, 
and individual cell membranes [4]. Drugs that are not soluble in water need to be made 
more soluble before being excreted, mainly through bile and/or urine. For some drugs, 
this metabolism takes place already in the gut wall and upon first passage through the 
liver (first-pass metabolism). The liver is the main drug metabolising organ in the body. 
About 73% of clinically used drugs are cleared via metabolism, 25% by renal excre-
tion, and a few per cent are excreted unchanged into the bile [5]. 
 
1.2.2.2 Clinical pharmacokinetics 
When a tablet or capsule is taken orally, absorption and metabolism occurs simultane-
ously as shown in Figure 1. Initially absorption dominates and later elimination prevails 
the concentration–time curve. The fraction of an orally given drug that reaches the 
systemic circulation is called the bioavailability (F). The total exposure of the drug can 
be described by the area under the curve from intake to infinity (AUC0-∞). The rate of 
elimination is described by the clearance* of the drug. Clearance (Cl) is defined as the 
systemically given dose (D) divided by the AUC, or for an orally given drug, 
∞−
×= 0AUCDFCl  
As the bioavailability cannot be determined without intravenous administration (F = 
100% when the drug is given i.v.), the expression oral clearance (Cl/F) is often used. 
An alternative way of expressing the rate of elimination is the elimination half-life (t½), 
which is the time needed for eliminating half the amount of drug in the body.  
 
Upon repeated dosing with a constant dosing interval (τ), the drug concentration will 
gradually increase with every new dose until a steady state is achieved. Under steady-
state, the mean drug concentration (Css) is constant and the amount of drug absorbed 
during the dosing interval equals the amount of drug that is eliminated. The apparent 
volume of distribution (Vd) is the imaginary volume that would be needed to dissolve 
the given dose to achieve the same concentration as in plasma. The apparent volume of 
distribution is important for the pharmacokinetic profile after a single dose, but does 
not influence the steady-state concentration. 
                                                 
*
 Epithelial, from Greek epi- (above) and thēlē (teat, nipple), refers to the epithelium, the outer cell lining 
of any gland or gland duct, including the gastro-intestinal canal. 
Figure 1  Plasma concentration plotted against time after single and repeated dosing. The shaded area in 
the left diagram is the AUC0-∞. The arrow in the right diagram indicates five half-lives, i.e. the time to 
reach steady-state. Solid line: dosing interval 12 hours, dashed line: dosing interval 24 hours. 
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Upon repeated dosing with a constant dosing interval (τ), the drug concentration will 
gradually increase with every new dose until a steady state is achieved. During steady-
state, the mean drug concentration (Css) is constant and the amount of drug absorbed 
during the dosing interval equals the amount of drug that is eliminated. The apparent 
volume of distribution (Vd) is the imaginary volume that would be needed to dissolve 
the given dose to achieve the same concentration as in plasma. The apparent volume of 
distribution is important for the pharmacokinetic profile after a single dose, but does 
not influence the steady-state concentration. 
These parameters relate to one another according to the following equations: 
 
τ×
×
=
Cl
DFCss    and   ClVt d×= 2ln½  
 
It follows that the steady-state concentration will increase with decreasing clearance, 
unless the dose is reduced or the dose interval prolonged. It can also be noted in the 
right diagram of Figure 1 that changing the dose interval will change the steady-state 
concentration, but not the time to steady-state, which (as a rule of thumb) is achieved 
after four to five half-lives. 
Clearance is largely dependent on individual factors. Clearance of drugs that are 
excreted by the kidneys is highly dependent on renal function. Liver metabolism is 
mainly genetically determined as shown by, among others Alexanderson et al., who 
could show that steady-state plasma concentrations of the antidepressant nortriptyline 
varied considerably more between fraternal than between identical twins [6]. 
 
1.2.3 Pharmacodynamics 
Pharmacodynamics is a wide field and deals with all aspects of how drugs affect 
organisms, including mechanisms of actions and concentration–effect relationships. 
The following description will be limited to the latter aspects. 
 
1.2.3.1 Concentration–effect relationship 
Most concentration–effect relationships are sigmoid (i.e. S-shaped) when the effect or 
response is plotted against the logarithm of concentration. This means that if there is no 
or very little drug in the body, there will be no drug effect. Once the concentration rises, 
a threshold will be reached and there will be a steep increase in effect with increasing 
concentration. Upon further increase in concentration, the effect will level off to reach a 
maximum. When the maximal effect is reached, there will be no further increase in 
effect no matter how high the concentration. However, most drugs have more than one 
effect, sometimes wanted but often unwanted. These side-effects ideally occur at higher 
concentrations than the desired effect as shown in Figure 2. 
 
1.2.3.2 Therapeutic interval 
As a result of the sigmoid shape of the concentration–effect relationship and the 
occurrence of side-effects at high concentrations, it is tempting to define a therapeutic 
interval for any given drug. At therapeutic concentrations there should be a decent 
                                                                                                                                           
*
 Clearance is a key pharmacological quantity that describes the capacity of drug elimination and is 
expressed in volume of cleared plasma (or blood) per unit time (e.g. L/h or mL/min). 
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beneficial effect and minimal side-effects. A therapeutic interval could therefore be 
defined as the concentration range between the level of minimal effect and the level of 
minimal side-effects. In Figure 2 this corresponds to about 1–10, where the upper limit 
depends on the tolerability of the side-effect. Dosing recommendations usually aim at 
reaching a steady-state concentration within the therapeutic interval.  
 
1.3 GENETICS 
1.3.1 Cytochrome P450 in general 
Many drugs are hydrophobic, i.e. poorly soluble in water, and need to be made hydro-
philic before being excreted in urine or bile. This conversion is in many cases catalyzed 
by a superfamily of haeme-containing enzymes called cytochrome* P450 because they 
give colour to the liver (and kidney) cell and absorbs light at a peak of 450 nm in their 
reduced carbon monoxide binding state [7, 8]. Cytochrome P450s (CYPs) are divided 
into families designated with numbers and subfamilies designated with letters based on 
their aminoacid sequence homologies. The individual enzymes are then numbered, e.g. 
CYP1A2, CYP2C9, CYP2D6, CYP3A4, and so on. The genes that encode these 
enzymes are called the same, but are written in italics (CYP1A2, CYP2D6). 
Cytochrome P450 enzymes are responsible for the clearance of about three quarters of 
the drugs that are cleared via metabolism (i.e. about 55% of all drugs) [5]. Genetic 
variants have been shown to largely influence the metabolic activity of cytochrome 
P450 enzymes. Polymorphic† drug metabolism of CYP substrates was first reported for 
the tricyclic antidepressants desipramine and nortriptyline [9], the antiarrhythmic drug 
sparteine [10] and the antihypertensive agent debrisoquine [11]. This polymorphism 
was explained by loss-of-function variants of the CYP2D6 gene [12-17]. Initially, 
subjects were divided into extensive metabolisers (EM) and poor metabolisers (PM), 
the latter of which are more prone to side-effects [12]. Later, ultrarapid metabolisers 
(UM) were discovered, who metabolise CYP2D6 substrates more rapidly than EMs 
and who are at risk of a subtherapeutic response at standard doses. UM phenotype‡ was 
shown to be associated with duplication of the CYP2D6 gene [18] and up to 13 gene 
copies have been found on the same chromosome [19]. Figure 3 shows the population 
distribution of CYP2D6 phenotypes. 
                                                 
*
 Cytochrome, from Greek kýtos (container, body, cell) and chrôma (color), i.e. a cellular pigment 
†
 Polymorphic, from Greek polýs (many) and morphos (form), refers to the simultaneous occurrence of 
different variants of a genetically determined trait in a population.  
‡
 Phenotype, from Greek phaínein (to shine) and typos (class, character), the observable or measurable 
constitution or trait of an individual, e.g. eye colour or CYP2D6 activity. 
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Figure 2  Schematic represen-
tation of concentration–effect 
relationships of a wanted 
(black) and an unwanted (grey) 
effect. Symbols represent half-
maximal effects and the posi-
tion on the other curve at the 
corresponding drug concen-
trations. 
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This thesis will focus on enzymes of another polymorphic cytochrome P450 subfamily 
(CYP2C), whose members are involved in the metabolism of 15-20% of clinically used 
drugs (or 25–30% of drugs metabolised by CYP enzymes) [5]. 
 
1.3.2 The CYP2C locus 
All members of the CYP2C family are encoded by genes that, in humans, cluster 
together on the long arm of chromosome 10 (10q24) [20]. The human CYP2C locus 
contains four genes: CYP2C8, 2C9, 2C18 and 2C19. All of these are polymorphic and 
the enzymes encoded by these genes are important for the metabolism of several drugs 
and other xenobiotics* [20-22]. The enzyme CYP2C18 has, however, not been unequi-
vocally shown in human tissues [21]. Some authors claim an association between 
variants of CYP2C18 and different pharmacological effects [23, 24], but this is 
probably due to linkage disequilibrium† between different point mutations (SNPs) 
within the CYP2C locus. The CYP2C18 gene can, however, be expressed in vitro‡ and 
                                                 
*
 Xenobiotic, from Greek xénos (foreign) and biōtikós (concerning life), refers to a substance not 
generated within the body. 
†
 Linkage disequilibrium (LD) refers to the situation when two (or more) traits occur together more often 
than would be expected from their frequency in the population, i.e. when the traits are non-randomly 
associated. Complete LD means that the traits are inherited dependently on each other. 
‡
 in vitro (within the glass): a procedure taking place in a test tube or Petri dish involving cultivated cells 
or cell preparations. 
Figure 3  Distribution of CYP2D6 phenotypes measured as the metabolic ratio of debrisoquine. Note 
that the ultrarapid metabolisers do not form a distinct group, but rather a tail to the left. Reproduced from 
Llerena et al., Pharmacogenomics 2009;10(1):17-28. 
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the gene product has enzymatic activity. Some substrates of the CYP2C enzymes are 
shown in Table 1. 
 
Substrate 
class CYP2C8 CYP2C9 (CYP2C18) CYP2C19 
Anti-
epileptics 
(phenytoin) phenytoin (phenytoin [25]) 
(R-mephenytoin) 
phenytoin 
S-mephenytoin 
Anti-
diabetics 
(tolbutamide) 
 
repaglinide [26] 
rosiglitazone [26] 
pioglitazone [26] 
tolbutamide 
glibenclamide [26] 
  
NSAIDs  diclofenac 
ibuprofen 
piroxicam 
celecoxib [27] 
  
Anti-
coagulants 
(R-warfarin) S-warfarin 
acenocoumarol [28] 
phenprocoumon [29] 
(R and S-
warfarin) 
R-warfarin 
Anti-
microbials 
amodiaquine 
chloroquine [30] 
 
 
(voriconazole [31]) 
 proguanil 
 
voriconazole [31] 
Proton 
pump 
inhibitors 
   
 
(lansoprazole [32]) 
omeprazole 
pantoprazole 
lansoprazole 
Anti-
depressants 
   citalopram 
imipramine 
chlomipramine 
Various 
(endogenous 
and 
exogenous) 
arachidonic acid [33] 
retinol 
retinoic acid 
 
benso(a)pyrene 
 
 
 
montelukast [34] 
paclitaxel 
arachidonic acid [33] 
 
 
∆
1
-tetrahydro-
cannabinol 
 
  
 
 
 
diazepam 
 
clopidogrel [35] 
propranolol 
 
Table 1  Substrate specificity of different CYP2C enzymes according to Goldstein et al. [21, 22], unless 
otherwise specified. Weak effects or effects only shown in vitro have been put within parentheses.  
1.3.3 CYP2C8 
To date (October 2010) 14 different alleles* have been described for CYP2C8 [36]. 
Some of them have been found to result in abolished or decreased enzyme function [36, 
                                                 
*
 Allele, from Greek allelos (each other), refers to a specific variant of a gene carrying one or more point 
mutations (SNPs). Each individual carries two alleles (one of maternal and one of paternal origin), which 
may or may not be the same. The first allele variant ever reported is designated *1 and is also called wild-
type. 
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37]. CYP2C8*3 that encodes an enzyme with reduced in vitro catalytic activity has an 
allele frequency* of 10-23% in Caucasian populations [30]. The results of clinical 
studies of the in vivo effect of this allele are inconsistent; It has been associated with 
increased clearance of the antidiabetics rosiglitazone and repaglinide [38]. However, in 
patients treated with the anticancer drug paclitaxel somewhat lower clearance [39] and 
higher risk of neurotoxicity [40] has been observed. The clinical impact of CYP2C8 
polymorphisms remains to be clarified [21, 41].  
  
1.3.4 CYP2C9 
The polymorphism of CYP2C9 was first described in the late 1970s for the metabolism 
of the oral antidiabetic agent tolbutamide [21]. This polymorphism was later discovered 
to be due to a rare allele now called CYP2C9*3 that carries a functional SNP. To date 
34 different CYP2C9 alleles have been described, all of them associated with decreased 
or abolished metabolic capacity [36]. Recently a case of ultrarapid CYP2C9 
metabolism was described but the genetic background remains to be elucidated [42]. 
 
1.3.4.1 CYP2C9*2 
The CYP2C9*2 allele was described by Rettie et al. in 1994 [43]. It has been shown to 
encode an enzyme with somewhat changed substrate specificity and a lower catalytic 
capacity than the wild-type enzyme, possibly because of a lower affinity for the cyto-
chrome P450 oxidoreductase [44]. For tolbutamide, CYP2C9*2 has been associated 
with a somewhat decreased clearance only in homozygous† individuals [26]. An epi-
demiological study showed no significant difference in the dose needed for glycaemic 
control in CYP2C9*2 carriers treated with oral antidiabetics [45]. In contrast, the clear-
ance of warfarin is reduced to the extent that a 20% lower maintenance dose is required 
in heterozygous‡ individuals and 36% lower in homozygous individuals [46]. In a 
Swedish population, the allele frequency of CYP2C9*2 is 9-13% [47]. 
 
1.3.4.2 CYP2C9*3 
As described above, the CYP2C9*3 allele encodes an enzyme with a prominent reduce-
tion in enzymatic capacity for all investigated substrates. On average, CYP2C9*3 
heterozygotes require 34% and homozygotes 78% less warfarin than wild-type 
carriers [46]. Carriers of CYP2C9*3 also have a greater risk of over-anticoagulation 
during warfarin treatment, both during initial and maintenance therapy [48, 49]. 
CYP2C9*3 carriers need dose adjustments more often and still have a tendency to have 
a larger hypoglycaemic effect of oral antidiabetics than non-carriers [45, 50]. The allele 
frequency is about 7,5% in a Swedish population [47]. 
                                                 
*
 Allele frequency for a variant allele is the number of variant alleles found divided by the total number of 
alleles investigated. A homozygous individual contributes with two alleles and a heterozygous with one 
allele. If one homozygote and ten heterozygotes are found among 100 subjects, the allele frequency will 
be (2+10)/(100×2) = 6%. 
†
 Homozygous, from Greek homós (one and the same) and zygón (yoke), refers to the carriage of two 
identical alleles of maternal and paternal origin. A homozygous individual is said to be a homozygote. 
‡
 Heterozygous, from Greek héteros (the other of two, different) and zygón (yoke), refers to carrying 
different alleles on the maternal and paternal chromosomes. 
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1.3.5 CYP2C19 
The polymorphism of this enzyme was first described for the metabolism of the anti-
epileptic drug mephenytoin [51]. Hence the enzyme is also known as mephenytoin 
hydroxylase. To date 28 alleles of CYP2C19 have been described [36]. Most of them 
are rare, however, and the following description will be limited to the most common 
alleles. Some rare alleles are common in special populations and may have clinical 
relevance in certain ethnic groups [52].  
 
1.3.5.1 CYP2C19*2 and CYP2C19*3 
CYP2C19*2 and *3 were originally described by de Morais et al. in 1994 [53, 54]. 
CYP2C19*2 results in a splicing defect of mRNA and CYP2C19*3 results in the 
insertion of a premature stop codon [21]. Thus no enzyme is produced from neither of 
these alleles. The allele frequency varies between different populations and in a 
Caucasian population poor metaboliser phenotype occurs at a frequency of 3-5%, while 
12-23% of most Asian populations are PMs. However, some Polynesian and Micro-
nesian populations have a frequency of PM genotype of up to 79% [55]. 
 
1.3.5.2 CYP2C19*17  
CYP2C19*17 was first described in 2006 and consists of two coupled SNPs in the 
upstream regulatory region of the CYP2C19 gene. The mutation at position -806 (C>T) 
results in the binding of nuclear proteins, which leads to increased expression of the 
gene and higher than average enzyme activity, whereas the other mutation (position 
-3402) is silent [56]. The two SNPs are in complete linkage disequilibrium in 
Caucasians and Ethiopians  [56], but not always in Sub-Saharan African 
populations [52]. Carriers of CYP2C19*17 are rapid extensive metabolisers but, as will 
be discussed in further detail in relation to Papers II and III, not ultrarapid 
metabolisers. The allele frequency of CYP2C19*17 has been estimated to 18-32% in 
European and Ethiopian populations but only 4% in Chinese [56, 57]. 
 
1.3.6 CYP2C haplotypes* 
The CYP2C alleles are in linkage disequilibrium with each other. As suggested in Paper 
II, the CYP2C19*17 allele is almost always inherited together with CYP2C8*1 and 
CYP2C9*1, at least in Nordic populations. Only one of 896 Nordic subjects carried the 
CYP2C19*17 allele together with CYP2C8*3 [58]. CYP2C19*2 is in complete linkage 
disequilibrium with CYP2C9*2 or CYP2C9*3. CYP2C8*3 is often inherited together 
with CYP2C9*2 [58, 59]. Pedersen et al. described ten different CYP2C haplotypes, of 
which 6 occured in 99% of Nordic subjects [58], see Table 2.  
 
                                                 
*
 Haplotype, from Greek haploûs (onefold, single), refers to a set of alleles inherited by an individual 
from a single parent. 
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Haplo-
type 
CYP2C19*17 CYP2C19*2 CYP2C9*2 CYP2C9*3 CYP2C8*3 No of 
haplotypes 
PHASE 
frequency 
STATA 
frequency 
1 – – – – – 869 0.4862 0.4866 
2 + – – – – 342 0.1901 0.1902 
3 – + – – – 286 0.1589 0.1595 
4 – – + – – 39 0.0218 0.0219 
5 – – – + – 102 0.0562 0.0558 
6 – – – – + 4 0.0023 0.0023 
7 + – – – + 1 0.0006 8.3E-30 
8 – + – – + 5 0.0026 0.0027 
9 – – + – + 142 0.0787 0.0791 
10 – + + – + 2 0.0012 0.0001 
Table 2  CYP2C haplotypes in a Nordic population (276 Danish, 309 Norwegian and 311 Faroese 
subjects). Allele frequencies calculated with two different methods (PHASE and STATA). Note that each 
individual carries two haplotypes, thus the sum is 896×2. Reprinted from Pedersen et al. [58]. 
 
1.4 DRUG INTERACTIONS 
This thesis will focus on drug interactions in the context of drug-drug interactions 
(DDIs), but food-drug and herb-drug interactions are not to be forgotten, as we have 
learnt from history. 
 
1.4.1 History 
Drug interactions were first recognized in the early 1960’s. Dramatic food-drug inter-
actions (severe headaches, hypertensive crises, intracranial haemorrhages and even 
deaths) were first described in 1963 following cheese consumption in patients treated 
with the antidepressant tranylcypromine and other irreversible monoamine oxidase 
inhibitors [60-62]. It could be shown that this was likely due to the tyramine content in 
cheese [63].  
The same year a Danish group published a case series and a clinical study of the drug-
drug interaction between the sulphonamide antibiotic sulphaphenazole and tolbuta-
mide [64] (Figure 4). This was the first description of a drug interaction mediated by 
CYP2C9 inhibition. Sulphaphenazole is now the standard CYP2C9 inhibitor used in in 
vitro systems [65].  
Figure 4  (A) Sulphaphenazole-induced increase in serum tolbutamide and decrease in blood glucose. 
(B) Effect of i.v. sulphaphenazole on the elimination half-life of tolbutamide. Reproduced from 
Christensen et al., Lancet, 1963;2(7321):1298-301. 
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It was soon realised that drugs (and other exogenous compounds) may both induce and 
inhibit the metabolism of other drugs, thus complicating pharmacotherapy [66]. 
Extensive and ultrarapid metabolisers are generally more sensitive to inhibitory drug 
interactions than poor metabolisers [67], a fact that still isn’t fully realised by the 
medical community (e.g. [68]). In some instances, a metabolic pathway can play a 
minor role in EMs, but act as an escape route in PMs. Inhibition of such an escape route 
may have a stronger impact in poor metabolisers. An example of this is the anti-
depressant venlafaxine that is mainly metabolised by CYP2D6 and to a lesser extent by 
CYP3A4. In some CYP2D6 PMs, the co-administration of the CYP3A4 inhibitor keto-
conazole causes a major inhibition of venlafaxine metabolism [69]. Another exception 
is when poor metabolisers have a low, but not absent, enzymatic capacity. One example 
of this is the interaction between the oral anticoagulant agent acenocoumarol and 
NSAIDs metabolised by CYP2C9. None of these drugs inhibit CYP2C9, but given 
concomitantly they increase the risk of overanticoagulation in CYP2C9*2 and CYP
2C9*3 carriers, but not in homozygous wild-type carriers [70]. 
 
1.4.2 CYP2C8-mediated drug interactions 
Only a few CYP2C8-mediated drug interactions of clinical importance have been 
described. Concomitant treatment with sulfamethoxazole/trimethoprim and the oral 
antidiabetic agent repaglinide resulted in symptomatic hypoglycaemia [71], probably 
due to trimethoprim inhibiting CYP2C8. Gemfibrozil, an antilipaemic* agent, also 
inhibits CYP2C8 and affects the pharmacokinetics of repaglinide [72], ibuprofen [73] 
and montelukast [34], an oral antiasthmatic agent, that is a well established in vitro 
inhibitor of CYP2C8 [65], but that does not seem to inhibit CYP2C8 in vivo† [74]. 
There has been concern that the anticancer drug sorafenib (kinase inhibitor) may inhibit 
the CYP2C8 dependent metabolism of paclitaxel (also known as taxol, a cytostatic 
agent derived from the Pacific yew-tree, Taxus brevifolia), but this has not been shown 
in pharmacokinetic studies [75, 76], although higher mortality rates were observed 
when combining the two drugs in patients with advanced squamous cell lung 
cancer [77]. 
One of the probably most clinically significant CYP2C8-mediated inhibitory drug-drug 
interactions might have been the interaction between the lipid-lowering agents gemfib-
rozil (a potent inhibitor of CYP2C8 in vivo [41]) and cerivastatin. The latter of these 
drugs was withdrawn from the market in August 2001 due to an unexpectedly high 
number of rhabdomyolysis‡ cases, many of which were associated with cerivastatin 
used in a high dose or in combination with gemfibrozil [41, 78]. 
CYP2C8 is also readily induced by certain drugs, especially rifampicin [41], but 
clinical evidence is lacking about the impact on drug metabolism in vivo. 
 
                                                 
*
 Antilipaemic, from Greek antí (opposite), lípos (fat) and haîma (blood), refers to the ability to lower 
blood fat levels. 
†
 in vivo, Latin (in the living): an experiment involving the whole, intact organism. 
‡
 Rhabdomyolysis, Latin from Greek rhábdos (rod, stick), mŷs (muscle), and lýsis (loosening or 
breakage), rapid breakdown of skeletal muscle, often associated with acute renal failure. 
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1.4.3 CYP2C9-mediated drug interactions 
In contrast to CYP2C8-mediated drug interactions, there is a voluminous literature on 
CYP2C9-mediated drug interactions. Some examples are given below. 
 
1.4.3.1 Antidiabetics 
The first CYP2C9-mediated drug-drug interaction was described in the late 1950’s 
between tolbutamide and isoniazid [79], although the mechanism was not known at the 
time. The concomitant medication with oral antidiabetics and CYP2C9 inhibitors is still 
a major issue, as illustrated in a Finnish study where 20% of patients treated with 
glibenclamide (glyburide in the US), glimepiride or glipizide received a known 
CYP2C9 inhibitor during admission to hospital, resulting in exaggerated pharmaco-
dynamic effect [80]. It seems that drug interactions that inhibit the metabolism of oral 
antidiabetics are more important clinically than interactions with drugs that induce the 
metabolic capacity of antidiabetic agents, as both rifampicin  [81] and St John’s 
wort [82] have been shown to substantially decrease exposure to glimepiride and 
gliclazide, respectively, but the investigators have been unable to show a corresponding 
change in pharmacodynamics in healthy volunteers. On the other hand, a diabetic 
patient had to double his gliclazide dose while concomitantly treated with rif-
ampicin [83] and Park et al. could show both pharmacokinetic and pharmacodynamic 
effects in healthy volunteers given single doses of gliclazide before and after 6 days of 
rifampicin [84]. Possible reasons for these discrepancies are 1) differences in study 
design (with or without oral glucose tolerance testing), 2) rifampicin being a more 
potent inducer than St John’s wort, 3) differences in the 
pharmacokinetic/pharmacodynamic relationship in diabetics and healthy volunteers. 
The reason for the relative lack of case reports of therapeutic failure in diabetic patients 
treated with oral agents may be that there are many other reasons for suboptimal 
therapeutic response in type-2 diabetes than DDIs and that hypoglycaemia is more 
likely to be symptomatic than hyperglycaemia [85]. 
 
1.4.3.2 Warfarin 
One of the most studied CYP2C9 substrates in relation to drug interactions is warfarin. 
Warfarin is an important drug that has revolutionised the treatment of thromboembolic 
diseases [86]. The most active warfarin enantiomer*, S-warfarin, is mainly metabolised 
by CYP2C9 [43, 48, 87, 88]. Since warfarin has a narrow therapeutic interval, it is 
particularly prone to drug interactions. To date (October 2010) 219 drug-drug or herb-
                                                 
*
 Enantiomer, from Greek enantíos (opposite) and méros (part), one of a pair of optical isomers that 
mirror each other. When mixed in a 1:1 proportion the mixture of the two enantiomers (or stereoisomers) 
is called a racemate, from Latin racemus (bunch of grapes) over French acid racémique (tartaric acid). 
There are three different systems to depict stereoisomers: 1) optical activity: (+) or d for dextrorotatory 
and (-) or l for levorotatory, 2) comparison with glyceraldehyde: D or L, or 3) arranged according to 
atomic number prioritization: R and S for Latin rectus (right) and sinister (left). None of these systems 
have any fixed relation to the others. The R/S system is more general as it can be used to specify several 
optical centers in the same molecule, and has the advantage of not confusing the sometimes opposite 
meaning of a lower case letter (l/d) with a small capital letter (L/D), e.g. D-fructose is l-fructose and has 
four optical centers, thus (2R,3S,4R,5R)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol. 
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drug interactions are listed in the Swedish-Finnish Interaction X-referencing Database 
(SFINX) [89], most of them pharmacokinetic, but also many pharmacodynamic inter-
actions. Inhibitory interactions include those with the antibiotic sulfamethoxazole/
trimethoprim, the antifungal drug fluconazole, and the antiarrhythmic amiodarone. 
Substances that can induce the metabolism of warfarin include St John’s wort, the 
tuberculostatic drug rifampicin and the anti-HIV-drug nevirapine [89]. 
 
1.4.3.3 Phenytoin 
Another important CYP2C9 substrate is the antiepileptic drug phenytoin. Phenytoin has 
a narrow therapeutic interval and has the pharmacokinetically interesting property to 
saturate its own metabolism even at concentrations within the therapeutic range, thus 
making plasma concentrations rise disproportionately to an increase in dose [1]. The 
SFINX interaction database lists 239 known interactions with phenytoin. Most of them 
are due to the ability of phenytoin to induce CYP3A4 and thus decrease the plasma 
levels of many other drugs [89]. However, amiodarone, isoniazid, sulfamethoxazole/
trimethoprim, fluconazole, and the antidepressant fluoxetine have been associated with 
inhibition of phenytoin metabolism, whereas nelfinavir and rifampicin can decrease 
phenytoin plasma levels by inducing CYP2C9 [89].  
A recent case report of ultrarapid phenytoin metabolism illustrates that extensive and 
ultrarapid metabolisers are prone to inhibitory drug interactions. Despite being treated 
with high doses of phenytoin (600–700 mg daily) the patient had very low plasma 
levels. On two separate occasions she received fluconazole for fungal infections and 
was intoxicated by phenytoin (Figure 5) [42]. 
 
 
Figure 5  Schematic illustration of two phenytoin–fluconazole interaction episodes. (A) In March 2000, 
the patient showed central nervous system (CNS) symptoms a few days after the initiation of flucon-
azole treatment, despite phenytoin concentrations within therapeutic range (40–80 µmol/L, shaded area). 
The CNS symptoms were probably caused by the rapid increase in phenytoin plasma levels. (B) In May 
2008, the patient developed severe signs of phenytoin toxicity after a few days of concomitant 
fluconazole treatment. From Helldén et al., Eur J Clin Pharmacol., 2010; 66(8):791-5. 
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1.4.4 CYP2C19-mediated drug interactions 
1.4.4.1 The clopidogrel–PPI interaction 
There has been considerable scientific controversy in recent years about the interaction 
between the irreversible platelet aggregation inhibitor clopidogrel and proton-pump 
inhibitors (PPIs), especially omeprazole; first whether there is an interaction or not, and 
second whether this interaction is of clinical relevance. Clopidogrel is used in cardio-
vascular diseases for preventing myocardial and cerebral (re-)infarction. PPIs are often 
given to the same patients to prevent gastrointestinal haemorrhage due to aggressive 
antithrombotic treatment, which often include aspirin, clopidogrel, low molecular-
weight heparin, and sometimes even antagonists of the platelet glycoprotein IIb/IIIa 
receptor [90]. Currently, there are over 200 articles in PubMed* regarding the clopido-
grel–PPI combination. The adverse interaction was first noted in 2006 by Gilard et al. 
who could show higher platelet aggregability in omeprazole users compared to non-
users when treated with clopidogrel [91]. These preliminary ex vivo† findings have 
since been reproduced by several investigators [92-94]. Hulot et al. showed an 
association between CYP2C19*2 and clopidogrel resistance [95], and Mega et al. could 
show a relation between CYP2C19 genotype, plasma levels of the active thiol meta-
bolite of the inactive prodrug clopidogrel, and clinical outcome [35]. Omeprazole (or its 
sulphone metabolite) is an inhibitor of CYP2C19 [96, 97] and hence possibly of 
clopidogrel bioactivation. An increased risk of a new cardiovascular event has been 
observed in carefully performed epidemiological studies in patients receiving concomi-
tant therapy with clopidogrel and PPIs [98, 99]. Indeed, if the entire difference in the 
observed risk of a new cardiovascular event were ascribed to the interaction, this would 
correspond to an abolished clopidogrel effect [98]. However, these findings could not 
be reproduced in a retrospective re-analysis of two randomized controlled trials [100]. 
To further complicate matters, clopidogrel has been shown to inhibit the metabolism of 
omeprazole [101], possibly further increasing the CYP2C19 inhibition by shunting 
omeprazole to the CYP3A4-generated sulphone metabolite. In conclusion, omeprazole 
inhibits the bioactivation of clopidogrel, diminishes clopidogrel response ex vivo, but 
the clinical implication of this is still unclear. It has been suggested that this potential 
interaction may be avoided by separating the intake of clopidogrel and omeprazole, but 
this has not been investigated. Indeed, although omeprazole acts as a competitive‡ 
inhibitor in vitro [97], omeprazole administration has been shown to inhibit CYP2C19 
in vivo in a time-dependent§ manner [96, 102, 103]. 
 
                                                 
*
 PubMed is a free database of biomedical citations supplied by the US National Library of Medicine. 
†
 ex vivo, Latin (out of the living), refers to an experiment or measurement done on cells or tissues taken 
out of the living organism. 
‡
 Competitive inhibition: A situation when the inhibitor competes with the substrate for the same binding 
site. Competitive inhibition can be overcome by increasing the concentration of the substrate in relation 
to the inhibitor. Cf non-competitive inhibition: when the inhibitor binds to a site different from the 
substrate, thus changing the conformation of the enzyme (or transporter) and the affinity for the substrate. 
§
 Time-dependent inhibition: Any type of inhibition that involves a dimension of time, often mechanism-
based inhibition, i.e. when the inhibitor forms a (relatively) stable enzyme-inhibitor complex, thus 
inactivating the enzyme. 
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1.4.4.2 Omeprazole and diazepam 
It is fascinating how some scientific information can disseminate into population 
groups far from academia. When I was at the Detox Unit in Falköping in the south-west 
of Sweden during my internship, I heard from the patients that you could get a better 
rush from diazepam (Valium®) if you took omeprazole (Losec®) concomitantly. The 
pharmacokinetic background to this phenomenon was elucidated in the late 1980’s and 
early 1990’s, when it could be shown first that diazepam metabolism was related to 
mephenytoin hydroxylase (CYP2C19) phenotype [104]. It was soon shown in inter-
action studies that the clearance of diazepam was decreased in a dose-dependent 
manner by 25-50% after seven days of omeprazole [105, 106]. This raised the idea that 
omeprazole was metabolised by CYP2C19, too. A clinical trial confirmed this in 
1990 [107]. No studies have been found that correlate this interaction to an increased 
pharmacodynamic effect, but it might be clinically relevant, especially as it seems to be 
common knowledge among substance abusers. 
 
1.4.4.3 Oral contraceptives 
Combined oral contraceptives (OCs) have been shown to significantly inhibit the 
CYP2C19-mediated metabolism of mephenytoin and omeprazole [108, 109]. In one 
study healthy volunteers, previously phenotyped for CYP2C19 activity with mepheny-
toin and/or omeprazole, were stratified according to sex and OC use. The ratios of S/R-
mephenytoin and omeprazole/5-hydroxyomeprazole were 2.5- and 2-fold higher, 
respectively, in women taking OCs compared to men and women not taking OCs [108]. 
This has also been reproduced in a placebo-controlled trial showing very similar 
results [109]. No general sex difference in CYP2C19 activity has been consistently 
found [108, 110]. However, during pregnancy, decreased CYP2C19 activity has been 
observed [111]. The mechanism for female sex steroids to affect drug metabolism has 
not been fully clarified. Palovaara et al. could show that the effect was mediated by the 
oestrogen component rather than the progestin of combined OCs [112]. 
Ethinyloestradiol (the oestrogen component of most combined oral contraceptive pills) 
has been shown to have some inhibitory effect on CYPs in vitro, but the IC50* for 
CYP2C19 is some 500-fold greater than the ethinyloestradiol concentrations achieved 
in vivo [113]. Recently, however, it could be shown that the CYP2C19 gene contains an 
oestrogen responsive element in its promoter† region and this was shown to be able to 
mediate down-regulation of gene transcription‡ at oestrogen concentrations of physio-
logical magnitude [114]. 
 
1.4.4.4 Phenytoin 
Phenytoin is mainly metabolised by CYP2C9 but CYP2C19 contributes to a lesser 
degree (approximately 15-20% of total clearance as estimated from in vitro 
                                                 
*
 IC50, inhibitory concentration 50%, the concentration needed to achieve half maximal inhibition. 
†
 Promoter: a regulatory region of DNA located upstream of a gene, providing a control point for 
regulated gene transcription. 
‡
 The central dogma of molecular biology: DNA is transcribed to mRNA, which is translated into 
polypeptides (called proteins if they are larger than or equal in size to insulin). The whole process 
including post-translational modification is called gene expression. 
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studies [115]) (Table 1). Phenytoin intoxications have been noted in patients prescribed 
CYP2C19 inhibitors, such as the SSRI fluvoxamine [116] and the platelet aggregation 
inhibitor ticlopidine [117, 118]. In the fluvoxamine case, phenytoin levels were 
increased from 65 to 194 µmol/L (therapeutic range 40-80 µmol/L) upon concomitant 
therapy with fluvoxamine 50 mg daily in a patient not carrying any mutant allele of 
CYP2C9 or CYP2C19 [116]. Fluvoxamine has been shown to be a moderate inhibitor 
of several CYPs, including CYP2C9 and CYP2C19 [119, 120]. There are two cases of 
phenytoin intoxication after the addition of ticlopidine resulting in severe intoxication 
symptoms and phenytoin plasma levels around 180 µmol/L [117, 118]. In the 
American case, CYP2C9 and CYP2C19 genotypes were found to be wild-type [118]. 
Ticlopidine has been shown to be a selective mechanism-based inhibitor (see footnote 
on page 13) of CYP2C19 [121], but a weak inhibitor of CYP2C9 [118]. This indicates 
that CYP2C19 may play a greater role in phenytoin metabolism than predicted from in 
vitro studies, especially in the upper part of the therapeutic range, where CYP2C9-
mediated phenytoin metabolism may be saturated. 
Phenytoin is also an inducer of several CYP enzymes, including CYP3A4, CYP2C9 
and CYP2C19. When combining an enzyme inducer with an enzyme inhibitor, the 
results may be difficult to predict. This is illustrated by the combination of the anti-
fungal drug voriconazole (which is primarily metabolised by CYP2C19 and an 
inhibitor of CYP2B6, CYP3A4, CYP2C9 and CYP2C19 [122]) with phenytoin: 
Healthy volunteers received either voriconazole (200 mg b.i.d.*) and placebo or vori-
conazole and phenytoin (300 mg q.d.†) for 21 days. Those who received phenytoin 
continued for another week with voriconazole 400 mg b.i.d. The exposure (AUC) to 
voriconazole on day 21 was decreased by 70% in the subjects receiving phenytoin. This 
could be compensated for by doubling the voriconazole dose, but this resulted in an 
80% increase in the phenytoin exposure [123]. Thus monitoring of plasma concen-
trations are often mandatory when combining strong inducers and strong inhibitors to 
avoid underdosing of the inhibitor or overdosing of the inducer. 
 
1.4.5 Noscapine 
Noscapine (a.k.a. narcotine) is a naturally occurring opium alkaloid with cough-
suppressing effects, but without central opioid effects [124]. It accounts for up to 20% 
of the alkaloid content in latex from opium poppy (Papaver somniferum) 
varieties [125] and up to 40% of the alkaloid content of poppy seeds [126]. In spite of 
its, at the most, moderate effect [127] noscapine is a commonly used anti-tussive in 
Scandinavia with 96% of annual sales sold over-the-counter (OTC) [128]. Noscapine 
has recently been shown to have anti-tumoural properties and is currently under 
investigation in two clinical trials in hematological malignancies [129, 130]. The drug 
interaction potential of noscapine was first investigated in 1967, when it could be 
shown that noscapine increased the blood-pressure lowering effect of neostigmine in 
cats [131]. Otherwise the drug interaction potential of noscapine does not seem to have 
been investigated. 
 
                                                 
*
 b.i.d., Latin bis in diē (twice daily); t.i.d., ter in diē (three times daily), q.i.d., quattōr in diē (four times 
daily) 
†
 q.d., Latin quaque diē (every day), i.e. once daily 
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1.4.6 Glucosamine 
Glucosamine is an aminosugar that is a component of endogenous glucosaminoglycans, 
such as heparan sulphate and hyaluronic acid [132, 133]. It was first used in the late 
1950’s as it was shown to increase the systemic availability of tetracyclines [134]. In 
recent years, glucosamine has gained interest in treating osteoarthritic pain as it has 
been shown to stimulate the formation of cartilage in vitro and in some ex vivo and in 
vivo animal studies [135-137]. However, controlled clinical trials in man have not 
unequivocally shown a positive effect [138]. Reports from all over the world have 
raised the suspicion that glucosamine might interact with warfarin to increase the 
anticoagulant effect. This effect has been seen after several weeks of combined 
use [132, 139-141]. In a single single case report a decreased anticoagulant effect was 
observed when acenocoumarol (another oral anticoagulant similar to warfarin) was 
combined with a glucosamine sulphate preparation [142]. The mechanism for the 
potential interaction between glucosamine and oral anticoagulants is unknown. 
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2 AIMS 
The overall aim of this thesis was to investigate inter-individual differences in CYP2C 
dependent drug metabolism and the influence of specific genetic variants and drug 
interactions, with special emphasis on OTC drugs. The ultimate goal of this work has 
been to reach a better understanding of the reasons for intra- and inter-individual 
variations in pharmacokinetics and to improve the safety of pharmacotherapy. 
 
The specific aims of the individual studies were: 
 
Paper I: To investigate whether homozygous carriers of the low-function allele 
CYP2C9*3 would accumulate celecoxib (a COX-2 selective non-steroidal anti-
inflammatory drug) given repeatedly in a normal dose. 
 
Paper II: To prospectively investigate the influence of the novel CYP2C19*17 allele 
on the pharmacokinetics of a single dose of omeprazole and to decide whether the 
earlier estimates of increased omeprazole metabolism could be verified. 
 
Paper III: To prospectively investigate the influence of the novel CYP2C19*17 allele 
on the steady-state pharmacokinetics of S-citalopram (escitalopram) and decide 
whether the preliminary claims of ultrarapid metabolism of omeprazole could be 
translated to another clinically important CYP2C19 substrate. 
 
Paper IV: To try to answer the question “Does noscapine interact with warfarin?” and 
to propose a pharmacokinetic mechanism for the suspected interaction based on in vitro 
inhibition assays.  
 
Paper V: To investigate the pharmacokinetic effects of noscapine and glucosamine on 
in vivo CYP enzyme activity measured with different probe drugs. The cocktail of CYP 
probe drugs was based on the validated “Karolinska cocktail” and the components 
chosen according to potential relevance for warfarin metabolism. 
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3 METHODS 
3.1 SUBJECTS 
Subjects for the studies in Papers I–III and V were recruited from a database of 
previously pheno- and/or genotyped individuals that had participated in earlier studies 
(e.g. [143-145]) at the Clinical Pharmacology Trial Unit (CPTU), Karolinska Univer-
sity Hospital, Huddinge. They were pre-screened by telephone by a research nurse to 
assure that they were interested in participating in and eligible for the respective study. 
If interested and eligible, they came to a screening visit were they were given written 
and oral information and gave written consent before any study-related procedures 
were undertaken. Subjects were included in the study if physical examination and bio-
chemical screening, including a urinalysis of illicit drug use, were approved. All studies 
were performed according with the contemporary versions of the WMA Helsinki 
Declaration and ICH-GCP guidelines and applicable local legislation. 
All clinical trials were approved by the Regional Ethics Committee and by the Swedish 
Medical Products Agency (Läkemedelsverket). 
 
3.2 STUDY DESIGNS 
3.2.1 Paper I 
This study was an open study of celecoxib 200 mg once daily for seven days given to 
healthy volunteers stratified according to CYP2C9 genotype. Plasma sampling for 
pharmacokinetic analyses was made after the first (pre-dose and at 1, 2, 3, 4, 10 and 24 
hours) and after the last dose (at the same time points with extra sampling at 48 hours 
post-dose). 
Inclusion criteria were in brief: written informed consent, CYP2C9*1/*1, *1/*3 or 
*3/*3 genotype, good medical condition, negative urinalysis for drugs of abuse and 
ECG and biochemical analyses without clinically significant aberrations. 
Exclusion criteria included: smoking, body mass index (BMI) >30 kg/m2, abnormal 
serum lipids, hypertension, history of cardiovascular disease, concomitant medication 
(including oral contraceptives, herbal remedies and glucosamine within two months), 
pregnancy, and lactation. 
 
3.2.2 Papers II–III 
This was a two-phase pharmacokinetic study with single dose omeprazole (40 mg) and 
repeated dose escitalopram (5 mg b.i.d. for 6½ days). Pharmacokinetic plasma 
sampling was done at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hours after ingestion of two tablets 
of Losec® MUPS® 20 mg (AstraZeneca AB, Södertälje, Sweden) in the first phase. In the 
second phase, plasma samples were drawn on the seventh day before and at 1.5, 3, 4, 5, 
8, 10 and 12 hours after the morning dose of Cipralex® 5 mg (H. Lundbeck A/S, 
Copenhagen, Denmark). Subjects were allowed to participate in the second phase no 
earlier than one week after participating in the first phase. Informed consent was 
obtained separately for each study phase. 
Inclusion criteria, in brief: written informed consent, CYP2C19*1/*1 or *17/*17 
genotype, good medical condition, negative urinalysis for drugs of abuse and ECG and 
biochemical analyses without clinically significant abnormalities. 
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Exclusion criteria included concomitant medication other than paracetamol during the 
last two weeks. Female subjects were required to abstain from oral contraceptives for at 
least three weeks and produce a negative pregnancy test before inclusion.  
 
3.2.3 Paper IV 
This study was based on the Swedish adverse drug reactions register, a thorough 
literature search, two different data mining approaches and in vitro inhibition tests. 
These different methodologies are described in more detail below. 
 
3.2.4 Paper V 
The study in Paper V was an open label two-part study in healthy volunteers. The 
subjects were phenotyped with a validated combination of CYP activity markers based 
on the Karolinska cocktail [145]. Since the CYP2D6 probe debrisoquine was no longer 
available, and CYP2D6 does not play a role in the metabolism of warfarin, we used a 
cocktail consisting of the four drugs caffeine (for CYP1A2), losartan (for CYP2C9), 
omeprazole (for CYP2C19) and quinine (for CYP3A4). After initial phenotyping, the 
subjects were given noscapine 50 mg t.i.d. (Noskapin ACO®, ACO AB, Solna, 
Sweden) for 7½ days and were again phenotyped on the last day while still on 
noscapine. The design is outlined in Figure 6. At least three weeks after participating in 
the noscapine study, subjects were eligible for the glucosamine part. In the glucosamine 
study, the subjects were again phenotyped before and on the last day of glucosamine 
625 mg b.i.d. (Artrox®, Pfizer AB, Sollentuna, Sweden) for 30 days. After two weeks 
subjects paid a visit to the CPTU for a compliance check and for INR and CRP testing. 
We included healthy men and women between 18 and 65 years of age that were willing 
to abstain from caffeine for 16 hours before phenotyping and who tested negative for 
drugs of abuse, and gave written informed consent. 
Main exclusion criteria were: any clinically significant medical condition (either known 
or discovered during screening), concomitant use of any medication other than 
adrenergic nasal sprays or paracetamol, and (for female participants) a positive 
pregnancy test during any part of the study. 
 
 
Figure 6  Schematic study design of the noscapine phase in Paper V. Baseline phenotyping was done in 
the morning after 16 hours of caffeine abstinence: 100 mg of caffeine was taken at 7 am, 25 mg of 
losartan and 20 mg of omeprazole was taken at 8 am. Plasma sampling for caffeine and omeprazole was 
done at 11 am and urine was collected from 8 am until 4 pm for losartan analysis. 100 mg of quinine was 
taken at 4 pm and plasma was sampled at 8 the following morning. This procedure was repeated during 
days 7 and 8 while on concomitant noscapine (at 7 am, 2 and 10 pm). 
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3.3 ANALYTICAL METHODS 
3.3.1 Genotyping 
Subjects were re-genotyped for the gene of interest in studies II–III and V. Genotyping 
analyses were based on polymerase chain reaction (PCR*). The currently applied 
routine method (mostly allelic discrimination assay on TaqMan; Applied Biosystems, 
Foster City, CA) at the Clinical Pharmacology Laboratory, Karolinska University 
Hospital, was used for CYP2C9*2, CYP2C9*3 and CYP2C19*2. For CYP2C19*17 a 
newly developed method was applied, which is described in more detail in Paper II. 
 
3.3.2 Drug analyses 
All drug analyses were based on High-Performance Liquid Chromatography with UV 
(HPLC) or mass spectrometric detection (LC-MS or LC-MS/MS). 
 
3.3.2.1 Celecoxib 
A new reversed-phase HPLC method for celecoxib and its two metabolites, hydroxy 
(OH)-celecoxib and carboxy (COOH)-celecoxib, was elaborated by Mia Sandberg 
Lundblad and is described in more detail in her thesis [146]. Briefly, plasma (0.5 mL) 
was mixed with 1.5 mL acetonitrile and centrifuged for 5 minutes at 15,000 × g. The 
supernatant was transferred to new tubes and evaporated using a vacuum centrifuge.  
Samples were reconstituted in 200 µL of methanol, and 50 µL thereof was injected into 
the HPLC-system. All samples were run in duplicates. A gradient mobile phase was 
used, where mobile phase A consisted of 10% acetonitrile and 90% 0.01 M sodium 
hydrogen phosphate buffer (pH 5.4). Mobile phase B consisted of 80% acetonitrile and 
20% 0.01 M sodium hydrogen phosphate buffer (pH 5.4). The gradient elution started 
with 20% B for 7 minutes, after which it was increased to 50% for 5 minutes. At 12 
minutes, mobile phase B was gradually increased to 70% until 19 minutes, when it was 
decreased to the initial value of 20%. The total run time was 20 minutes, at a constant 
flow-rate of 1 mL/min. Absorbance was measured at 254 nm. Retention times were 
approximately 6.8, 11 and 17 min for COOH-celecoxib, OH-celecoxib, and celecoxib, 
respectively. The range of quantification was 0.025 to 20 µM for each analyte. The 
lower limit of quantification (LLOQ) was 0.025 µM. The intra-day variability was 
7.5%, 10.3% and 6.2% for celecoxib, OH-celecoxib and COOH-celecoxib, respect-
ively, and inter-day variability for the corresponding substances was 9.8%, 9.7% and 
8.8%.  
 
                                                 
*
 Polymerase chain reaction (PCR) is a method to amplify a specific region of DNA by adding region-
specific primers, deoxyribonucleotides in excess and thermically stable Taq polymerase (a DNA poly-
merase from the bacterium Thermus aquaticus living in the hot springs of Yellowstone National Park) 
and then repeatedly heating the mixture to around 95ºC to separate the double stranded DNA helix, then 
cooling to about 51ºC to allow the primers to attach to the DNA strands, then heating to around 72ºC to 
allow the polymerase to work properly, and then heating to 95ºC again to separate the newly formed 
DNA strands and so on. In just a few cycles there will be thousands to millions of copies of the DNA 
region of interest. 
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3.3.2.2 Omeprazole 
Omeprazole and the two metabolites, 5-hydroxyomeprazole and omeprazole sulphone, 
were analysed by reversed-phase HPLC based on previously published methods and is 
described in some detail in Paper II. Briefly, 100 mL of plasma was extracted with 
alkalinised methylene chloride:acetonitrile (9:1, v/v). After centrifugation and 
aspiration of the aqueous phase, the organic phase was evaporated at 60ºC. Samples 
were reconstituted in methanol and analysed with reversed-phase HPLC. Absorbance 
was monitored at 302 nm. The range of quantification was of 10–2,500 nmol/L. LLOQ 
for all three analytes was 10 nmol/L. The intra-day and inter-day variation (CV) for 
omeprazole and the two major metabolites were <10% and <15%, respectively. 
 
3.3.2.3 Escitalopram 
Escitalopram and its metabolites, desmethylcitalopram and didesmethylcitalopram, 
were analysed according to the contemporarily applied routine method at the Clinical 
Pharmacology Laboratory at the Karolinska University Hospital and based on the 
method by Macek et al. [147]. Briefly, plasma samples were extracted to diethyl-
propylether after alkalinisation followed by extraction into acidic aqueous phase. 
Escitalopram and its desmethyl and didesmethyl metabolites were subsequently ana-
lysed using reversed-phase HPLC. Internal standard was (S)-(-)-3-bromo-N-[(1-n-
propyl-2-pyrrolidinyl)-methyl]-2,6-dimethoxybenzamide (AstraZeneca AB). The range 
of quantification was 10–2,000 nmol/L for all analytes. LLOQ was 4 nmol/L for citalo-
pram and 7 nmol/L for desmethyl- and didesmethylcitalopram. Accuracy was 95–
100%, and inter-day variability (CV) was approximately 5%. 
 
3.3.2.4 Noscapine 
A novel tandem mass spectrometry (LC-MS/MS) method was developed by master 
student Stella Otto and her supervisors Michèle Masquelier and Jennie Östervall and is 
described in detail in her master thesis [148]. 
Noscapine was extracted from plasma using solid phase extraction (SPE). Plasma 
samples (400 µL) were added 50 µL of internal standard (diphenhydramine hydro-
chloride) and 400 µL 2% formic acid. SPE columns (Oasis MCX; Waters, Milford, 
MA) were activated with 1 mL of methanol and washed with 1 mL of water before the 
addition of the prepared samples. The SPE columns were washed with 1 mL 2% formic 
acid and 1 mL methanol. Noscapine was then eluted with 1 mL 2% ammonium acetate 
in methanol. The eluates were concentrated in a vacuum centrifuge for 2×15 min and 
placed in injection vials for analysis on an Acquity UPLC BEH column (Waters; 2.1 × 
50 mm, 1.7 µm) by LC-MS/MS, using a Waters Acquity UPLC system (Waters). Raw 
data were gathered by MassLynx v4.1 software (Waters). Noscapine was eluted with a 
mobile phase of 0.1% formic acid and methanol (gradient 45–80% methanol) at a flow 
rate of 0.4 mL/min. The mass transitions monitored were m/z 414–220 for noscapine 
and 256–167 for the internal standard. Noscapine recovery was 108%. Stability tests 
showed that noscapine plasma samples could be stored for 5 days at +4 °C. The method 
was linear in the range 0.35–500 ng/mL (0.85–1,200 nmol/L), with a coefficient of 
determination (r2) of 0.9993, and the limit of detection was 0.1 ng/mL. Total 
imprecision was 5.1% and 8.9% for noscapine concentrations of 75 ng/mL (181 
nmol/L) and 3.75 ng/mL (9 nmol/L), respectively. 
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3.3.2.5 Karolinska cocktail 
The cocktail analyses were performed according to the methods described by 
Christensen et al. [145]. That is, the analysis method for omeprazole in Paper V differs 
slightly from the method applied in Papers II–III. The most important difference being 
that they were analysed in different laboratories and on different hardware and that the 
LLOQ of the method used in Paper V was 25 nmol/L (compared to 10 nmol/L in 
Papers II–III). LLOQ for losartan and its carboxy metabolite (E-3174) was 20 and 10 
nmol/L, respectively. LLOQ for quinine and 3-OH-quinine was 5 nmol/L, and 0.5 
nmol/L for caffeine and paraxanthine. 
 
3.4 STATISTICAL METHODS 
3.4.1 General statistics 
In all papers we have taken care to apply the relevant statistical methods. Since we have 
been looking for quite large differences between groups and within individuals under 
different circumstances, we have applied simple t-tests for normally distributed data 
and tried to transform non-normally distributed data to reasonably normal distribution. 
When we have succeeded, we have applied t-tests as above. When transformation has 
not been successful, we have applied standard non-parametric statistics (Mann-Whitney 
U-test for comparison between two groups and Kruskal-Wallis for comparison between 
more than two groups). Within the limits of this thesis, we have not found a need for 
more advanced statistical methods as the studies have been limited to healthy volun–
teers without co-morbidities. 
The one exception was the methods used in Paper IV, which will be described next. 
 
3.4.2 Data mining 
Adverse drug reactions (ADR) registers are based on spontaneously reported adverse 
events (AE) during pharmacotherapy that the reporter suspects has a relation to the use 
of the drug. Not all reported events have a true relation to the use of the suspected drug. 
Reporting is mandatory for all AEs during the first years after market authorisation, 
thereafter only for serious ones. The reporting of a certain AE (or combination of AEs) 
in relation to a certain drug more often than could be expected by chance is in this 
context referred to as a signal. In other words a signal can be said to occur when a 
certain drug–AE combination is reported disproportionately often. ADR registers can 
therefore be said to contain some signals obscured by lots of noise. Different methods 
have been developed for signal detection (which is virtually based on peak-to-noise 
enhancement techniques developed for radar and radio communication). When digging 
into a large database, this process is called data mining, or rather, disproportionality 
analysis. In the field of pharmacovigilance*, such techniques have been in use since the 
mid 1990’s [149]. In Paper IV, we applied two different methods: Proportional 
reporting ratio (PRR) and Bayesian confidence propagation neuronal network 
(BCPNN). 
                                                 
*
 Pharmacovigilance, from Greek phármakon (drug) and French vigilance (attentiveness), the science and 
activities relating to the detection, assessment, understanding and prevention of adverse effects or any 
other drug-related problem. 
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3.4.2.1 Proportional reporting ratio 
A reporting rate can be calculated by dividing the number of reported adverse events 
with the number of prescriptions or sales volumes of a certain drug. This ratio is biased 
however, by delays in sales statistics and more frequent reporting of AEs for new 
drugs. Another approach is to take the proportion of the number of reports of an AE of 
interest for a certain drug divided by the total number of reports for that drug. This 
proportion can further be enhanced by dividing it with the proportion of all reports of 
the AE of interest for every other drug to all other reports of any other AE in the 
database. This ratio is called the proportional reporting ratio (PRR) [149]. 
The mathematics behind the PRR are explained in Table 3. Accordingly, the PRR will 
be 1 if there is no association between the drug and the reaction of interest. Evans and 
co-workers suggested that a signal is worth investigating when the PRR is greater than 
2, χ2 is greater than 4, and the number of reports of the drug–AE combination of inter-
est (a) is greater than 3 [149]. For a two-by-two table (with 1 df*), the critical value of 
χ
2
 
is actually 3.84 for a significance level of α = 0.05 [150], so the criteria by Evans et 
al. implies slightly stricter criteria than are generally considered statistically significant. 
 
 
 Drug of 
interest 
All other 
drugs 
Reaction(s) 
of interest a b 
All other 
reactions c d 
Table 3  Calculation of proportional reporting ratios according to Evans et al. Pharmacoepidemiol Drug 
Saf, 2001;10(6):483-6. The formula for chi-squared (χ2) is redrawn from Machin et al. [150]. 
Explanations: r is the number of rows, c is the number of columns, Oij is the observed count in cell ij, and 
Eij is the expected count in cell ij under the assumption of chance distribution. 
 
3.4.2.2 Bayesian confidence propagation neuronal network 
Bayesian statistics are named after Reverend Thomas Bayes (1702-1761), who realised 
that the probability for event A (lets say an afternoon rain shower) is different when you 
know condition B (you can see heavy clouds at the horizon coming closer), than if you 
do not know about B. He stipulated Bayes’ theorem: 
 
, where 
 
)(Ap is the probability of A, called prior probability as it does not take account to B, 
)( BAp is the conditional probability of A, given B, also called the posterior probability 
)( ABp is the conditional probability of B, given A, also called the likelihood, and 
)(Bp is the prior probability of B. 
                                                 
*
 df, degree(s) of freedom, is a statistical/mathematical concept that is not easily explained within the 
constraints of  a footnote, but the interested reader can find the most elegant explanation in Wikipedia 
(www.wikipedia.org). 
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Now, back to the ADR register: if p(x) is the probability of a specific drug being listed 
on a case report; p(y) is the probability of a specific ADR being listed on a case report; 
and p(x,y) is the probability of both the drug and the ADR being listed on a case report, 
then we can construct a measure of disproportionality called the information 
component (IC): 
 
 
 
The IC will be close to zero if there is no association between the drug and the ADR, it 
will be positive if there is a positive relation, and negative if the drug is less associated 
with the ADR than expected. 
Using a computerised neuronal network, the IC can be calculated as a point estimate 
with a confidence interval or a probability distribution. The Bayesian approach allows 
for the applicability of low (and zero) counter values, calculation with missing data 
(confidence interval will be wide), analysis of other and multiple variables, and there is 
an intuitive relationship between the IC estimate and its confidence interval. The 
neuronal network also allows for automatic signal detection [151]. 
 
3.5 IN VITRO EXPERIMENTS 
In Paper IV we applied commercially available kits (Vivid® CYP450 Screening Kit, 
Invitrogen Corp, Madison, WI) for in vitro inhibition screening of CYP2C9 and 
CYP3A4, the main enzymes involved in the metabolism of S- and R-warfarin, 
respectively. The Vivid® screening kit contains microsomes called Baculosomes® 
prepared from insect cells transfected* with baculoviruses and expressing recombinant 
human CYP enzymes. The kit also contains all reagents needed including a fluorescent 
dye linked to a blocker that is a substrate for the specific CYP enzyme. When the 
blocker is cleaved, the dye is released and becomes fluorescent. If the enzyme is 
inhibited, less dye is released and thus the sample becomes less fluorescent [152]. The 
kit comes in different colours. We used the green kit for both CYP2C9 and CYP3A4. 
 
3.6 SOFTWARE 
3.6.1 Statistical software 
For statistical analyses we used Statistica (Statsoft Corp, Tulsa, OK), version 6.1 in 
Paper I and version 8.0 in Paper V. In Paper II statistical analyses were made with 
GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, CA) and Microsoft Excel 
(Microsoft Corp, Redmond, WA). StatsDirect version 2.6.5 (StatsDirect Ltd, 
Altrincham, UK) was used in Paper III.  
 
3.6.2 Pharmacokinetic analyses 
For pharmacokinetic analyses, we used WinNonLin (Pharsight Corp, Mountain View, 
CA). Version 4.1 was used in Paper I and version 5.1 in Papers II–III. GraphPad Prism 
5.03 (GraphPad Software Inc, La Jolla, CA) was used for curve-fitting purposes for 
                                                 
*
 transfection, refers to the transfer of a gene construct into a cell by infecting it with a virus containing 
the gene construct in question. Thus, human genes can be transfected to and expressed in e.g. insect, yeast 
or bacterial cells. 
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figures in this thesis together with an equation from Gabrielsson & Weiner [3] for a 
one-compartment oral pharmacokinetics model. 
 
3.6.3 Graphs 
Graphs were drawn with GraphPad Prism 5.0–5.03 (GraphPad Software Inc, La Jolla, 
CA) or Microsoft Excel (Microsoft Corp, Redmond, WA). 
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4 RESULTS 
4.1 PAPER I 
Initially we planned to include four to five subjects in all genotype groups. Due to the 
low allele frequency of CYP2C9*3 in a Swedish population (6–9% with <1% homo-
zygous individuals) [47] and the limited number of subjects in the database (about 200 
individuals), we were unable to recruit more than three subjects in the *3/*3 and *1/*3 
groups. This was somewhat compensated for by including seven subjects in the wild-
type group. 
Arithmetic means are sensitive to extremes, which is why we chose to analyse 
differences in median AUC between groups with the Kruskal-Wallis test. 
 
4.1.1 Single dose data 
Median AUC0-24 h differed 3.5-fold between the homozygous CYP2C9*3 carriers 
compared to heterozygous and wild-type individuals (Figure 7). 
 
4.1.2 Repeated dose data 
On day seven, the median AUC0-24 h was seven-fold higher in individuals homozygous 
for CYP2C9*3 compared to heterozygous and wild-type subjects. This is illustrated in 
the figure in Paper I. Figure 8 shows the metabolite levels of hydroxy- and carboxy-
celecoxib on day 7. Metabolites reached a lower maximal concentration in subjects 
genotyped as CYP2C9*3/*3 compared to the other genotype groups due to a lower 
formation rate. However, metabolite levels stayed higher for a longer time in homo-
zygous CYP2C9*3 carriers due to accumulation of the parent compound. 
Figure 7  Single dose data after the first dose of 200 mg celecoxib to healthy volunteers with different 
CYP2C9 genotypes (7 subjects in the *1/*1 group and 3 subjects each in the *1/*3 and  *3/*3 groups). 
Symbols and whiskers represent medians and interquartile ranges, respectively. The curves are fitted to a 
one-compartment oral model using all individual data. Symbols in the *1/*1 and *1/*3 groups are 
nudged to prevent overlap. 
0 4 8 12 16 20 24
0
1
2
3 CYP2C9*1/*1
CYP2C9*1/*3
CYP2C9*3/*3
Time (h)
Ce
le
co
xi
b 
(µM
)
   27 
Pharmacokinetic parameters for celecoxib after single and repeated doses are given in 
Table 4. 
 
 
 
CYP2C9 
genotype 
n T1/2 
(h) 
Cmax 
(µM) 
AUC0-24h 
(h*µmol/L) 
Cl/F 
(L/h) 
Day 1 *1/*1 7 13 (6.4–15) 1.8 (1.0–1.9) 12 (10–24) n.d. 
 *1/*3 3 7.5 (4.6–20) 1.6 (0.97–1.7) 12 (11–17) n.d 
 *3/*3 3 30 (25–37)*† 2.1 (1.4–3.1) 41 (24–44) *† n.d. 
Day 7 *1/*1 7 14 (6.7–24) 2.0 (0.92–3.5) 18 (12–24) 29 (21–45) 
 *1/*3 3 10  (7.5–13) 1.9 (1.5–3.6) 17 (14–23) 32 (22–38) 
 *3/*3 3 52 (24–60) *† 7.7 (7.3–11) *† 125 (90–154) *† 4.2 (3.4–5.8) *† 
Table 4  Pharmacokinetic parameters for celecoxib after the first and seventh daily dose in subjects with 
different CYP2C9 genotypes. Cl/F: oral clearance, *: p < 0.05 compared to CYP2C9*1/*1 subjects, †: p < 
0.05 compared to CYP2C9*1/*3 subjects, n.d.: not determined. Oral clearance of celecoxib could not be 
determined after the first dose as the extrapolated AUC beyond 24 hours was too large. 
 
4.2 PAPER II 
Eighteen subjects were screened, one was excluded because confirmatory genotyping 
proved him to be heterozygous CYP2C19*17 carrier. Five subjects genotyped as 
CYP2C19*17/*17 and twelve homozygous CYP2C19 wild-type carriers were included. 
One of the subjects genotyped as CYP2C19*1/*1 displayed markedly aberrant ome-
Figure 8  Plasma levels of the celecoxib metabolites, hydroxycelecoxib and carboxycelecoxib, on the 
seventh day of repeated dosing of celecoxib 200 mg once daily in healthy subjects with different 
CYP2C9 genotypes. Symbols and whiskers represent medians and interquartile ranges, respectively. 
Symbols in the *1/*1 and *1/*3 groups are nudged to prevent overlap. Note the logarithmic scale on the 
y-axis. 
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prazole pharmacokinetics with extremely delayed absorption. This made the extra-
polated AUC10-∞ very large and thus unusable. The data analysis was thus based on five 
*17/*17 and eleven *1/*1 individuals. 
Several of the included subjects displayed bimodal omeprazole pharmacokinetics 
indicative of delayed absorption of one of the two Losec® MUPS® tablets. 
The mean AUC0-∞ for omeprazole was 52% lower in CYP2C19*17/*17 subjects than in 
wild-type subjects (p = 0.04). There was no significant difference in the AUC0-∞ of 5-
hydroxyomeprazole between genotype groups. However, the exposure of omeprazole 
sulphone, was 68% lower in the *17 carriers (p = 0.03). The corresponding difference 
in oral clearance of omeprazole was 48% higher in the *17/*17 group, which did not 
reach statistical significance (p = 0.37). 
One subject became pregnant after the follow-up visit and later gave birth to a healthy 
daughter. 
 
4.3 PAPER III 
The subject that was excluded from the data analysis in Paper II, participated in the 
escitalopram study, but the pregnant subject did not participate in the second part of the 
study. The escitalopram study thus comprised the same number of individuals in each 
genotype group as the omeprazole study, but only ten individuals genotyped as 
CYP2C19*1/*1 participated in both study parts. This explains the small differences in 
demographic characteristics between Paper II and Paper III. 
The mean difference in escitalopram AUC0-τ was 21% but this difference did not meet 
predefined criteria for statistical significance (p = 0.08).  
Eight subjects reported mild to moderate adverse events which were judged to have a 
possible relation to the study drug. No unexpected adverse events were reported. 
There was a significant correlation between the exposures of escitalopram at steady-
state and omeprazole after a single dose (Spearman r2 = 0.67, p = 0.006). There was a 
tendency for a curvilinear relationship, so that the subjects with the highest escitalo-
pram exposure tended to have an even higher omeprazole exposure (see Figure 2 in 
Paper III). This will be discussed more in detail in the Discussion section. 
 
4.4 PAPER IV 
4.4.1 Literature searches 
When searching the literature (PubMed, Embase and standard text books on drug 
interactions), we found nothing about a documented interaction between noscapine and 
warfarin. What we did find, however, was an animal study, that showed a decreased 
CYP content in rat liver after treating rats with very high noscapine doses (200 mg/kg) 
for five days [153]. We thought it difficult to interpret this finding in a clinically 
meaningful way. 
 
4.4.2 The Swedish ADR register 
In the Swedish ADR register (SWEDIS), there were five previous ADR reports con-
cerning the combined use of warfarin and noscapine. The oldest report was from 1978 
and the reported event was a haematoma. All other reports were about change in INR. 
However, the term in the database for increased anticoagulant effect is “prothrombin 
complex decreased” and one of the reports had been classified as “prothrombin com-
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plex increased”. When reading the full reports it was clear, however, that all reports 
were about increased anticoagulation* (i.e. “prothrombin complex decreased”). The 
classification of the misclassified report has been corrected in the register. Another two 
cases were reported during the summer of 2006 and are described in Paper IV, although 
the statistics were based on the first six cases. 
 
4.4.3 Data mining 
Table 5 shows the number of reports in SWEDIS as of June 2006 arranged according to 
specified properties. 
 
 Noscapine + warfarin All reports with ≥ 2 drugs 
(not warfarin + noscapine) 
INR increased and/or 
haemorrhage 6 2,241 
All other reactions 2 33,350 
Table 5 Number of reports in SWEDIS as of June 2006 arranged in accordance with Table 3. 
The proportional reporting ratio (PRR) could be calculated to 11.9 and χ2 to 63.8, 
which was highly significant (p < 0.001). The PRR could also be expressed as a 95% 
confidence interval (4.1–34.4). 
The information component (IC) value could be calculated to 2.16 with a 95% 
confidence interval of 0.73–3.59, i.e. also highly statistically significant. 
 
4.4.4 In vitro inhibition tests 
The in vitro inhibition tests showed that noscapine potently inhibits both CYP2C9 and 
CYP3A4 with IC50 values of 0.90 (95% CI 0.54-1.50) and 1.06 (95% CI 0.87-1.31), 
respectively (Figure 9). 
 
 
                                                 
*
 I can gladly recommend the interested reader who wants an in-depth explanation about the relation be-
tween levels of “prothrombin complex” and INR to read pages 11-12 in the thesis by Jonatan Lindh [86]. 
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Figure 9  In vitro inhibition tests using the Vivid® CYP450 Screening Kits for CYP2C9 and CYP3A4. 
Symbols and whiskers represent geometric means and standard deviations, respectively 
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4.5 PAPER V 
4.5.1 Subjects 
A total of fourteen subjects were included. Subjects gave separate informed consents 
for each study part. Eleven of the subjects participated in both study parts, and two 
subjects participated in only one of the study parts, either the noscapine part or the 
glucosamine part. Thus twelve subjects participated in the noscapine study and twelve 
in the glucosamine study. In both studies six subjects of each CYP2C9 genotype were 
included. Compliance with the study medication was over 96% in the noscapine part 
and about 80% in the glucosamine part. There were two screening failures; one subject 
had spontaneously and repeatedly elevated INR (about 1.5) and was referred to the Unit 
of coagulation, where she was diagnosed with von Willebrand disorder. Another 
subject was dismissed due to a positive urine test for illicit drug use. 
 
4.5.2 Phenotyping results 
4.5.2.1 Noscapine 
Baseline phenotyping results were in accordance with earlier findings from our 
department [143-145]. In the noscapine part, all subjects increased in losartan 
metabolic ratio*, on average 4.9-fold (95% CI 2.8–8.4, p < 0.001). One of the subjects 
had a very high metabolic ratio of losartan during noscapine treatment due to very low 
levels of the losartan carboxy-metabolite, E3174 (Figure 10). After exclusion of this 
subject, the mean increase in losartan metabolic ratio was still 3.9-fold (95% CI 3.0–
5.0, p < 0.001). The degree of inhibition was similar in individuals genotyped as 
CYP2C9*1/*1 compared to CYP2C9*1/*3 (see Figure 11). 
 
                                                 
*
 Metabolic ratio (MR) is the ratio between parent substance and metabolite. By convention, the ratio of 
paraxanthine/caffeine is used as a phenotypic marker for CYP1A2, and this is not a metabolic ratio, 
which is why we chose to use the term phenotypic index (PI) in Paper V. 
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Figure 10  Metabolic ratios of losartan and omeprazole at baseline and during noscapine, respectively. 
The outlier with almost 60-fold increase in the metabolic ratio of losartan is marked with an asterisk. 
Homozygous wild-type carriers are shown in black, while grey indicates subjects genotyped as 
CYP2C9*1/*3 in the losartan panel and CYP2C19*1/*17 in the omeprazole panel. 
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One of the subjects either forgot to take her omeprazole on the morning of the second 
phenotyping or had delayed absorption, as she had no detectable levels of either 
omeprazole or metabolites in her plasma. The plasma from another subject gave 
uninterpretable chromatograms due to interference and quantification could not be 
done. Thus, omeprazole data were assessable from ten subjects. All these subjects 
demonstrated an increased metabolic ratio of omeprazole on noscapine compared to 
baseline. The mean increase was 3.6-fold (95% CI 2.6–4.8, p < 0.001). There was a 
trend (p = 0.16) towards CYP2C19*17 carriers (three subjects) being inhibited to a 
higher degree than subjects genotyped as CYP2C19*1/*1 (Figure 11). 
 
There were no significant differences or trends in the phenotypic indices of caffeine or 
quinine during noscapine treatment compared to baseline (see Figure 1 in Paper V). 
 
4.5.2.2 Glucosamine 
There were no significant differences or any trends in phenotypic indices for any of the 
phenotyping drugs during concomitant glucosamine. Neither was there any change in 
C-reactive protein (CRP) levels or INR. 
 
4.5.3 Noscapine analyses 
The possibility to analyse noscapine emerged after all the paperwork with the 
authorities was done. Therefore no extra pharmacokinetic sampling was performed, but 
noscapine was analysed in the back-up samples for caffeine (4 hours post-dose on day 
7) and quinine (one hour after dose on day 8). 
Since noscapine is rapidly absorbed, reaching peak levels in less than an hour and has a 
relatively short half-life (4.5 hours) [124], we concluded that the 4-hour plasma level 
would better predict noscapine exposure than the 1-hour level. 
There was a correlation between 4-hour noscapine levels and multiples of increase in 
losartan metabolic ratio. However, the subject that had a metabolic ratio of nearly 60 
during concomitant noscapine treatment was also an outlier in this correlation. 
Interestingly, she had two to three-fold higher plasma levels of noscapine at one hour 
after intake than the other subjects. Excluding this subject from the regression analysis, 
there was a log-linear relation (r2 = 0.79, p < 0.001) between noscapine levels and 
CYP2C9 inhibition expressed as multiples in increase of the losartan metabolic ratio 
(See Figure 2 in Paper V). 
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Figure 11  Fold increase in 
the metabolic ratios (MRs) 
during noscapine compared to 
baseline. MRs of losartan and 
omeprazole are shown in rela-
tion to CYP2C9 and CYP2C19 
genotypes, respectively. 
Horizontal bars represent geo-
metric means. The grey bar in 
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presents the geometric mean 
without the outlier. 
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4.5.4 Adverse events 
In total, nine adverse events were reported during the noscapine study: headaches and 
stomach discomfort being most common. In the glucosamine study a total of 22 
adverse events were noted. The most frequent of these were: 3 cases each of nausea, 
frequent and/or loose stools and common cold; 2 events each of headache and 
abdominal pain. The most unexpected AE was one case of rank odour of the urine 
without any evidence of infection or renal impairment. Increased bilirubin was noted in 
one subject shown to carry the UGT1A1*28 allele associated with Gilbert’s syndrome*. 
No serious adverse events were noted. 
 
                                                 
*
 Gilbert’s syndrome is named after the French gastroenterologist Augustin Nicolas Gilbert (1858-1927) 
who described a hereditary form of jaundice which was later shown to be caused by decreased capacity to 
conjugate bilirubin to glucuronic acid due to defective uridine diphosphate-glucuronosyl transferase 1A1 
(UGT1A1). Gilbert’s syndrome affects some 5% of a Caucasian population and is normally without other 
clinical significance than transient jaundice during febrile illness. However, it has been associated with 
increased risk of toxicity in patients treated with the anticancer drug irinotecan and some antiviral 
drugs [154]. 
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5 DISCUSSION 
5.1 PAPER I 
Celecoxib is metabolised by CYP2C9 to hydroxycelecoxib (OH-celecoxib), which is 
further metabolised by alcohol dehydrogenase to carboxycelecoxib (COOH-celecoxib). 
Microsomes prepared from human livers genotyped as CYP2C9*3/*3 have been shown 
to metabolise celecoxib considerably slower than other human liver microsomes [155]. 
Our data on single-dose kinetics are in agreement with previous studies, that have 
reported two to three-fold higher AUC0-∞ of celecoxib in individuals genotyped as 
CYP2C9*3/*3 compared to CYP2C9*1/*1 [156, 157]. 
However, the steady-state data showing a seven-fold higher median AUC0-∞ of 
celecoxib in individuals homozygous for CYP2C9*3 compared to heterozygotes and 
homozygous wild-type subjects, contradict a previous study of celecoxib 200 mg b.i.d. 
for 15 days that could not demonstrate any difference in pharmacokinetics in a single 
elderly participant homozygous for CYP2C9*3/*3 compared to the genotype groups of 
the other 23 subjects [158]. 
At first glance, we were surprised at the marked accumulation of celecoxib at steady-
state in individuals homozygous for CYP2C9*3. However, the accumulation at steady 
state in homozygous CYP2C9*3 carriers can be simulated by repeatedly superimposing 
the single-dose data (Figure 12). This gives an approximate 6-fold difference in mean 
AUC0-24 h between the CYP2C9*1/*1 and CYP2C9*3/*3 groups. The original data from 
day 7 are depicted in Figure 1 in Paper I. 
It has been proposed that celecoxib may induce CYP3A4 [159] and that this 
mechanism may explain the discrepancy between our findings and the 15-day study by 
Brenner et al. [158]. CYP3A4 has been shown to metabolise celecoxib in vitro in 
CYP2C9 deficient human liver microsomes  [156] and in primary hepatocyte cultures 
treated with sulphaphenazole [159]. 
On September 30, 2004, rofecoxib (Vioxx®) was withdrawn from the market due to an 
increased risk of adverse cardiovascular events in a trial of rofecoxib for the prevention 
of colorectal polyps (the APPROVe study). This prompted the data and safety 
monitoring board of the similar Adenoma Prevention with Celecoxib (APC) trial to 
perform an assessment of cardiovascular safety with celecoxib. This review showing a 
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Figure 12  Simulation of 
celecoxib pharmaco-
kinetics on day 7 based on 
repeatedly superimposing 
single-dose data. 
Simulated means and 95% 
confidence intervals are 
shown. 
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dose-dependent increase in adverse cardiovascular events (hazard ratio* 2.3 in the 200 
mg b.i.d. arm and 3.4 in the 400 mg b.i.d. arm) with celecoxib [160], was long the only 
data published from the APC trial. Recently, new data have been published from the 
APC trial, which included 2,035 patients with a history of colorectal polyps and 
randomised to either of three arms; placebo, celecoxib 200 mg b.i.d., or celecoxib 400 
mg b.i.d. These new data include CYP2C9 genotyping data. 1,660 patients were 
successfully genotyped for CYP2C9*2 and *3. When analysing all patients regardless 
of genotype, there was a dose-dependently reduced risk for recurrent adenomas with 
celecoxib compared to placebo. After stratification by CYP2C9 genotype, the dose-
dependency of the reduced risk was limited to the CYP2C9*3 carriers. Celecoxib also 
increased the risk of adverse cardiovascular events in a dose-dependent way, which 
seems to be largely driven by the increased risk in CYP2C9*3 carriers given the high 
dose [161] (although this might be jumping to conclusions as the number of events was 
too small to reach statistical significance in any of the dose/genotype strata). 
When submitting the original full-length manuscript of Paper I, we tried to suggest that 
the pharmacokinetic differences between the genotype groups might have implications 
for cardiovascular and other adverse effects, but this speculation was disliked by the 
reviewers. The data from the APC trial show at least a tendency that we were right. 
The mechanism for how COX-2 selective NSAIDs pose a cardiovascular hazard is not 
fully understood, but one proposed mechanism is that it disturbs the balance between 
thromboxane A2 (which is primarily produced by COX-1 in platelets and stimulates 
platelet aggregation and vasoconstriction) and prostacyclin (which is produced 
primarily by endothelial† cells expressing COX-2, and inhibits platelet aggregation and 
dilates vessels). The mechanism may also involve interference with other arachidonic 
acid metabolites, many of which are formed and/or metabolised by CYP2C8 and 
CYP2C9 (see Table 1). 
 
5.2 PAPERS II AND III 
5.2.1 Our CYP2C19*17 study 
The CYP2C19*17 allele was discovered by sequencing the CYP2C19 genes of indi-
viduals found to be extensive metabolisers in earlier studies with omeprazole or 
mephenytoin as probe drugs. Based on retrospectively re-genotyping the subjects and 
re-analysing their phenotyping data, an approximate 40% mean difference in ome-
prazole exposure was estimated between genotype groups [56]. We designed the study 
behind Papers II and III to be able to detect such a large difference. This succeeded in 
the case of omeprazole. However, in the case of escitalopram, the mean difference in 
AUC was considerably smaller than estimated and this difference did not reach statis-
tical significance (p = 0.08). We considered recruiting more subjects to reach statistical 
significance, but this course of action would only result in chasing p-values. We had 
recruited almost all homozygous CYP2C19*17 subjects in our database and their data 
                                                 
*
 Hazard ratio (HR) refers in medical statistics to the odds ratio (OR) of an adverse event. Odds is the 
ratio of the probability of an event divided by the probability of a non-event, thus the hazard ratio 
between groups A and B is ( )( )BB
AA
pp
ppHR
−
−
=
1
1
 , while the relative risk (RR) is pA/pB. 
†
 Endothelial, from Greek éndon (within) and thēlē (teat, nipple), refers to the endothelium, the inner cell 
lining of blood vessels and heart chambers, confer the footnote on page 2 (epithelial). 
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were tightly grouped. Recruiting more CYP2C19 wild-type individuals would have 
yielded a p < 0.05, but it would have been unlikely to get a larger mean difference in 
escitalopram AUC. In order to get a larger effect in an extended study, we would have 
had to recruit subjects genotyped as CYP2C19*1/*1 with a lower than average 
CYP2C19 activity. We thus concluded that the CYP2C19*17 allele did not have a 
clinically significant effect on escitalopram pharmacokinetics. 
The primary metabolism of omeprazole is to a great extent catalysed by CYP2C19 to 
yield 5-hydroxyomeprazole (5-OH-omeprazole), whereas sulphoxidation of 
omeprazole to omeprazole sulphone is catalysed by CYP3A4. The R-enantiomer is 
hydroxylated to a greater extent than S-omeprazole [162, 163], while both enantiomers 
have equal pharmacological activity [164]. In the omeprazole study, it was interesting 
to note that there was a similar difference in the exposure to omeprazole sulphone 
(Paper II). This is probably due to CYP2C19 being responsible for a rate limiting step 
in the clearance of omeprazole sulphone to the secondary metabolite 5-hydroxyome-
prazole sulphone [165]. The correlation between the pharmacokinetics of omeprazole 
and omeprazole sulphone has also been shown in a study where healthy volunteers 
were first given omeprazole 40 mg once daily for seven days and in another study 
period 60 mg twice daily for seven days. This study showed reduced CYP2C19-
dependent clearance of omeprazole (2.3-fold) and sulphone (2.2-fold) when increasing 
the omeprazole dose. Simultaneously, the formation of 5-OH-omeprazole was delayed 
while its CYP3A4-dependent clearance was increased by 20% during high dose 
omeprazole treatment [103]. We can thus conclude that omeprazole is eliminated 
according to the scheme in Figure 13. 
 
The apparent curvi-linear relationship between escitalopram and omeprazole exposures 
described in Figure 2 in Paper III merits some discussion, although it is not excluded 
that it is a chance finding. The ability of omeprazole to inhibit its own metabolism at 
high exposures may be an explanation. Another possibility is saturation of omeprazole 
metabolism in those EMs that have the lowest metabolic capacity. 
 
5.2.2 CYP2C19*17 and PPIs 
The successful healing of peptic ulcers has been associated with CYP2C19 loss of 
function alleles using a relatively low dose of omeprazole (20 mg daily) in Asian 
populations with a high frequency of mutant alleles [166]. In Europe, where there is a 
lower prevalence of defective CYP2C19 alleles [167], doses of proton pump inhibitors 
are generally higher, but still CYP2C19*2 carriers have better ulcer healing according 
to two Polish studies of 125 and 139 patients, respectively  [168, 169]. It is unclear 
whether the second study includes the same patients as the first study, but the results 
are still interesting. These studies also show that neither heterozygous, nor homozygous 
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Figure 13  Schematic representation 
of omeprazole metabolism, where 
CYP2C19 mediates 5-hydroxylation 
of both omeprazole and omeprazole 
sulphone and CYP3A4 catalyzes 
sulphoxidation of both omeprazole 
and 5-OH-omeprazole. 
 36 
CYP2C19*17 carriers differ in ulcer healing rates from wild-type subjects, although 
plasma levels of pantoprazole were lower in the former group [169]. 
 
5.2.3 CYP2C19*17 and antidepressants 
5.2.3.1 Citalopram and escitalopram 
The results of our prospective trial seemingly contradicts the findings by Rudberg et al., 
who found a 42% difference in geometric mean plasma concentrations of escitalopram 
between CYP2C19*17/*17 and *1/*1 genotype groups in a therapeutic drug monitoring 
(TDM) material [170]. However, a TDM material may be biased in the sense that 
patients with lack of effect or side-effects may be more likely to be sampled, which 
may exaggerate differences in metabolic capacity. The wide sampling window 
(samples were taken 10–30 hours after intake) might also have introduced bias. 
It is interesting to note that individuals homozygous for CYP2C19*17 consistently have 
a relatively small interindividual variability in the metabolic capacity of CYP2C19 
substrates, whereas homozygous wild-type carriers are dispersed over a wide range of 
metabolic capacity with some individuals having a more extensive metabolism than any 
of the *17 homozygotes [35, 56, 170, 171] (Figure 14, and Papers II–III). It remains to 
be investigated whether these differences depend on hitherto undiscovered genetic 
variants or on environmental factors affecting CYP2C19 gene expression. 
 
  
(S-)-Citalopram is metabolised to desmethylcitalopram by CYP2C19 and further to 
didesmethylcitalopram by CYP2D6 [172]. Interestingly, adjusting for CYP2D6 geno-
type did not diminish interindividual variability in escitalopram plasma concentrations 
in the functional CYP2C19 genotype groups [173]. This might partly be explained by a 
novel CYP2C19-catalysed metabolic pathway to citalopram propionic acid [174]. 
Figure 14  Serum concentrations 
of (a) escitalopram and (b) N-des-
methylescitalopram in relation to 
CYP2C19 genotype. Lines indi-
cate geometric means. Note the 
relatively small spread within the 
*17/*17 group and the consider-
able overlap between wild-type 
and CYP2C19 *17 carriers. 
Reproduced from Rudberg et al. 
Clin Pharmacol Ther, 2007; 
83(2):322-7. 
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5.2.3.2 Sertraline 
Sertraline is an SSRI that is primarily metabolised by CYP3A4, but also by several 
other CYPs, including CYP2C19 [175]. Carriage of defective CYP2C19 alleles have 
been associated with higher exposure of sertraline [176, 177], while no effect could be 
demonstrated for CYP2C19*17 in a TDM study in 121 patients [177]. 
 
5.2.3.3 Imipramine 
Recently, the impact of CYP2C19*17 on the pharmacokinetics on imipramine was 
reported. Imipramine is a tricyclic antidepressant that is metabolised by CYP2C19 to 
the active metabolite desipramine. Patients were prospectively prescribed imipramine 
in doses from 25 to 900 mg daily and were sampled at steady-state aiming for trough* 
concentrations of the sum of imipramine+desipramine between 200 and 300 µg/L 
(about 700–1100 nmol/L). It was found that patients homozygous for CYP2C19*17 had 
30% lower imipramine levels than patients classified as CYP2C19*1/*1, but the 
concentrations of the active moiety (imipramine+desipramine) did not differ between 
CYP2C19 genotype groups [171]. 
 
5.2.4 CYP2C19*17 and other drugs 
5.2.4.1 Clopidogrel 
The platelet aggregation inhibitor clopidogrel is a prodrug, i.e. it needs to be activated 
by metabolism in order to be pharmacologically active. This bioactivation is mediated 
by several CYPs in vitro [178]. However, in vivo, CYP2C19 genotype has been shown 
to influence pharmacodynamics [95, 179-181], pharmacokinetics of the active meta-
bolite, as well as clinical outcome in clopidogrel treated patients [35, 180]. This speaks 
in favour of CYP2C19 being the most important enzyme for clopidogrel bioactivation 
in vivo. The CYP2C19*17 allele has been associated with enhanced clinical effect [35, 
180, 182], but also increased risk of bleeding in patients treated with clopidogrel [180].  
Just recently, three more studies on the clopidogrel–CYP2C19 genotype theme have 
been published almost simultaneously: one is a re-analysis of the 10,285 patients from 
the PLATO trial comparing clopidogrel to a reversible platelet aggregation inhibitor, 
ticagrelor, that does not need bioactivation [183]; the other is a genetic substudy of 
2,932 participants in the TRITON-TIMI 38 trial comparing clopidogrel with a similar 
compound, prasugrel that is less dependent on CYP2C19 for bioactivation [178, 184]; 
the third is a genotype analysis of 5,059 participants from the pivotal clopidogrel study 
(CURE) [185]. The first study (funded by the manufacturer of ticagrelor) concludes 
that ticagrelor is superior to clopidogrel irrespective of CYP2C19 genotype, and that 
clopidogrel is associated with a higher risk of major bleedings in CYP2C19*17 
carriers [183]. The second study (funded by the manufacturers of prasugrel) concludes 
that nearly half of the population is at risk of unfavourable response to clopidogrel (and 
                                                 
*
 Trough does not, in this context, refer to the feeding of farm animals, but to the to the lowlands of the 
concentration–time curve after each dose, i.e. the end of the dosing interval, before the next dose; as 
opposed to the peak, the timing of which depends not only on the rate of elimination, but also on the rate 
of absorption. Trough concentrations are easier to sample and are more reproducible than peak concentra-
tions that are very sensitive to the timing of the sampling. See also Figure 1 on page 1. 
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should be treated with prasugrel) [184]. Finally, the third study (funded by the 
manufacturers of clopidogrel) fails to see a relation between CYP2C19 genotype and 
neither lack of response, nor major bleeding in the first study attempting a comparison 
of clopidogrel to placebo after stratification by CYP2C19 genotype [185]. However, it 
is striking how the favourable clopidogrel effect in the CURE trial seems to have been 
driven by clopidogrel treated CYP2C19*17 carriers, as neither of the other genotype 
groups had an effect that significantly differed from placebo. The strict definition of 
major bleeding (haemorrhage requiring transfusion of at least 2 units of blood) may 
have contributed to the negative correlation between genotype and bleeding events. 
Another interesting finding of this latter study, was that clopidogrel seemed to have 
some beneficial effect in preventing major coronary events regardless of CYP2C19 
genotype, as there was a consistent trend for the clopidogrel treated patients to do better 
than the placebo treated patients, although this was significant only for *17 
carriers [185].  
 
5.2.4.2 Voriconazole 
The broad spectrum antifungal agent voriconazole is primarily metabolised by CYP
2C19 with some contribution from CYP3A4 [31]. Wang et al. genotyped 315 subjects 
to recruit 20 healthy volunteers with genotypes CYP2C19*1/*1 (n = 8), *2/*2 (n = 8) 
and *1/*17 (n = 4). Due to the scarcity of the *17 allele in Asian populations, no homo-
zygous individuals were found. The results showed 48% lower AUC0-∞ in CYP2C19
*17 carriers compared to wild-type subjects [186]. These data might not be directly 
applicable to Caucasian populations, as Asian extensive metabolisers of CYP2C19 
substrates generally have a lower metabolic capacity than Caucasian EMs [167], even 
after stratification for genotype [187], and the *17 allele might therefore have a larger 
impact in Asians. 
 
5.2.4.3 Tamoxifen 
Tamoxifen is an oestrogen receptor antagonist that needs to be bioactivated for full 
efficacy. It is used as adjunctive therapy in breast cancer when the tumour expresses the 
oestrogen receptor [188, 189]. Tamoxifen is primarily metabolised by CYP2D6 to yield 
the 100-fold more potent metabolites 4-hydroxytamoxifen and 4-hydroxy-N-des-
methyltamoxifen (endoxifen), but CYP2C19 also contributes [190, 191]. 
In a retrospective analysis of 206 tamoxifen-treated and 280 non-tamoxifen treated 
patients, CYP2D6 genotype was strongly associated with relapse-free survival. It was 
also found that CYP2C19*17 carriers had a better relapse-free survival than non-
carriers, especially if they were carriers of fully functional CYP2D6 alleles [188]. This 
finding could not be reproduced in a smaller case–control study (47 breast cancer 
patients and 135 matched controls), where the participants were selected from a trial of 
tamoxifen prevention in 5,408 women of average breast cancer risk. However, there 
was still a trend for a beneficial effect of CYP2C19*17 carrier status (OR* 3.50, 95% 
CI 0.46–26.6) [189]. 
CYP2C19 is also involved in the metabolism of oestrogens [192, 193] and if CYP2C19
*17 proves to be a marker of favourable response to tamoxifen, it remains to clarify 
                                                 
*
 OR (odds ratio), the ratio between the odds for the cases divided by the odds for the controls, cf footnote 
on page 34. 
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whether this is due to an increased bioactivation of tamoxifen, increased catabolism of 
oestrogens, or other factors coupled to the *17 allele. Indeed, CYP2C19*17 has been 
associated with decreased risk of developing breast cancer (OR 0.64, 95% CI 0.44–
0.94) [194]. 
 
5.2.5 The clinical impact of CYP2C19*17 
As written above, the CYP2C19*17 allele is associated with a uniform and higher than 
average expression and metabolic activity. However, not even homozygous *17 
carriers have a more rapid metabolism than the most extensive metabolisers genotyped 
as *1/*1. Thus, it is inappropriate to attribute CYP2C19*17 carriers an ultrarapid 
metaboliser pheno-type. It may be warranted to compare with the distribution of 
CYP2D6 phenotype, where the UMs form a tail at the extreme of extensive metabolic 
capacity (see Figure 3). Therefore, even if CYP2C19*17 proves to be clinically 
significant on a population level, it will hardly prove to be clinically significant on an 
individual level. In selected cases, however, retrospectively genotyping for 
CYP2C19*17 may provide an explanation for treatment failures or lower than expected 
plasma levels of therapeutic drugs. We have not yet reached the end of the CYP2C19–
clopidogrel story, but pre-emptive CYP2C19 genotyping (at least for the loss of 
function alleles *2 and *3) may prove to be cost-effective, especially as clopidogrel has 
recently come off patent and is likely to become considerably cheaper than its alter-
natives. The more expensive alternatives could thus be reserved for those unlikely to 
benefit from clopidogrel therapy. 
 
5.3 PAPER IV 
5.3.1 Warfarin metabolism 
Warfarin is the drug that causes the greatest number of serious adverse drug reactions  
in Sweden [195], the only exception being 2009, when the pandemic flu vaccine had 
more serious ADR reports [196]. This was probably more a result of the high reporting 
rate for the new flu vaccine than it being extraordinarily harmful. Warfarin is a race-
mate where S-warfarin is a more potent anticoagulant than R-warfarin. S-warfarin is 
metabolised by CYP2C9, whereas R-warfarin is mainly metabolised by CYP3A4 and 
CYP1A2 with some contribution from CYP2C19 [88]. 
 
5.3.2 ADR reports and disproportionality analyses 
Since first reporting our findings of an association between noscapine use and increased 
effect of warfarin at the annual meeting (Riksstämman) of the Swedish Society of 
Medicine in late 2006, two more case series have been published. Scordo et al. reported 
of four cases of increased INR during concomitant noscapine and warfarin treatment 
and on the return to therapeutic levels after withdrawal of noscapine [197]. Myhr 
reported the same finding in four cases from Norway [198]. Until October 2010, there 
have been 20 reports in Sweden, 7 reports in Norway, and 1 report in the Netherlands 
of this suspected interaction [199, 200]. 
Although the disproportionality analyses do not prove causality, the association is 
strengthened by the fact that the signal is significant with two different methods. We 
have not recalculated the PRR and IC after the last reports, but they would be higher, 
since there are more reports showing an association and no reports that there is not. 
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5.3.3 In vitro findings 
Our suspicion of a pharmacokinetic interaction between noscapine and warfarin was 
supported by the in vitro findings. Yet, we only used one test system and it couldn’t be 
completely ruled out that noscapine may disrupt the test system in some other way than 
enzyme inhibition. Recently, Fang et al. have reproduced and elaborated our initial in 
vitro findings with proper enzyme inhibition kinetics using human liver microsomes 
(HLMs). First they tested the ability of 100 µM of noscapine to inhibit the metabolism 
of seven different CYP probe substrates (phenacetin for CYP1A2, coumarin for CYP
2A6, paclitaxel for CYP2C8, diclofenac for CYP2C9, dextromethorphan for CYP2D6, 
chlorzoxazone for CYP2E1, and testosterone for CYP3A4). In the presence of 
noscapine, the catalytic capacity was reduced with more than 80% for diclofenac 4’-
hydroxylation (CYP2C9) and testosterone-6β-hydroxylation (CYP3A4). Further 
studies were therefore performed to elucidate the inhibition kinetics of noscapine 
towards CYP2C9 and CYP3A4. Mixed HLMs were preincubated with different con-
centrations of noscapine (0–50 µM) for various times (0–20 min) before 10-fold 
dilution and testing of residual catalytic capacity. The results showed a time-dependent 
inhibition of both CYP2C9 and CYP3A4 activities as shown in Figure 15. 
 
 
Figure 15  Time-dependent inhibition of CYP3A4 and CYP2C9 by noscapine. (A) Time- and concen-
tration dependent inhibition of CYP2C9 by noscapine. (B) The hyperbolic plot of kobs (the observed 
inactivation rate) of CYP2C9 vs. noscapine concentrations. (C) Time- and concentration-dependent 
inhibition of CYP3A4 by noscapine. (D) The hyperbolic plot of kobs of CYP3A4 vs. noscapine 
concentrations.  Reproduced from Fang et al., Br J Clin Pharmacol., 2010; 69(2):193-9. 
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The authors predicted a 42% and 33% increase in S- and R-warfarin, respectively, at the 
maximal plasma concentration reached after a single 50 mg dose of noscapine [201]. 
However, noscapine does not have a linear dose–concentration relationship, as the 
bioavailability increases with increasing or repeated doses [124]. Pharmacokinetic 
studies of noscapine with more than two consecutive doses have not been published. 
This contributes to the uncertainty of extrapolating in vitro findings to in vivo 
conditions. 
 
5.3.4 Causality and confounding 
The association between increased anticoagulant effect of warfarin and concomitant use 
of noscapine could possibly be explained by confounding by indication, i.e. the respira-
tory infection that caused the cough might have reduced the clearance of warfarin by 
inflammatory downregulation of CYP gene expression. Inflammation has been shown 
to lower the expression of several CYPs [202] and decreased drug clearance has been 
noted during respiratory infection (influenza B) [203]. 
However, we did not find any reports of an interaction between warfarin and any other 
opioid cough syrups, neither in the literature, nor in the ADR registers. Recently, 
however, there was a report about increased INR in three maintenance warfarin treated 
patients concomitantly using a cough syrup containing ethylmorphine and Senega 
extract (Cocillana-etyfin®) [204]. This report warrants further investigation. 
 
The results of Paper IV prompted the Swedish Medical Products Agency (MPA) to ask 
the manufacturer of warfarin to add a warning for concomitant use of noscapine to the 
warfarin Summary of Product Characteristics (SPC). It also made the board of the 
MPA willing to finance the study that resulted in Paper V. 
 
5.4 PAPER V 
5.4.1 Noscapine 
We could clearly show that noscapine inhibits CYP2C9 dependent losartan metabolism 
and CYP2C19 dependent omeprazole metabolism. The concept of metabolic ratios is a 
useful measure of the activity of different CYP enzymes. However, it is not readily 
interpreted from a clinical point of view. In an attempt to evaluate the possible clinical 
impact of the degree of CYP2C9 inhibition seen in the study, we compared our data 
with the geno–phenotyping data of Yasar et al. [144]. The results of this comparison is 
illustrated in Figure 16 and described numerically in Paper V.  
The basal metabolic ratio of losartan (MRlosartan) of the CYP2C9*1/*1 subjects in our 
study was very similar to that of the previous study. On concomitant noscapine, the 
MRlosartan increased to numbers comparable to the CYP2C9*2/*3 group in Yasar’s 
study. A recent metaanalysis of the impact of warfarin dose in relation to CYP2C9 
genotype showed that CYP2C9*2/*3 carriers on average have less than 50% of the 
dose of CYP2C9 wild-type individuals [46]. This comparison justified the declaration 
that the observed inhibition of CYP2C9 by noscapine was clinically significant. 
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When it comes to a similar comparison regarding the omeprazole data, it is more 
difficult to draw any clearcut conclusions. Comparing our data with the CYP2C19 
geno–phenotyping study by Chang et al. [143], showed that the inhibition of ome-
prazole metabolism was comparable to converting an extensive metaboliser to inter-
mediate metaboliser phenotype.  This may still be of clinical importance for drugs with 
narrow therapeutic intervals. The bioactivation of clopidogrel is one example. Several 
drugs are dependent on both CYP2C9 and CYP2C19 for bioactivation, e.g. the cyto-
static drugs cyclophosphamide and ifosfamide [205], or elimination, e.g. 
phenytoin [115]. 
It is interesting to note that we did not observe any in vivo inhibition of CYP3A4 
activity, neither measured with the quinine/3hydroxyquinine ratio, nor with the 
omeprazole/omeprazole sulphone ratio (data not shown). The omeprazole/omeprazole 
sulphone ratio has been proven useful for CYP3A4 phenotyping under both inhibition 
and induction conditions [206]. The quinine/3-hydroxyquinine ratio has been shown 
sensitive for induction [207], but has not previously been used for inhibition studies. 
The lack of demonstrable in vivo CYP3A4 inhibition is in contrast to both our 
preliminary in vitro data presented in Paper IV and above and to the data of Fang et 
al. [201]. Since CYP3A4 is highly expressed in the gut [208], one highly speculative 
explanation might be that noscapine concentrations are high enough to inhibit enteric* 
CYP3A4, thus reducing first-pass metabolism, while leaving enough hepatic† CYP3A4 
activity for unaffected systemic quinine metabolism. Our data might support this idea, 
as quinine concentrations were higher after noscapine than on basal phenotyping (p ≈ 
0.03), while the quinine/3-hydroxyquinine ratio was unaffected. This may well be a 
chance finding and would need a complete pharmacokinetic profile to verify. Another 
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Figure 16  Comparison of losartan phenotyping data from the geno–phenotype study by Yasar et al. 
(light grey symbols) and our noscapine interaction study (dark grey symbols). Bars represent geometric 
means. The light grey bar in the *1/*1 group on noscapine represents the geometric mean when the 
outlier is excluded. 
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possible, and maybe less speculative, explanation might be that noscapine is a 
mechanism-based (i.e. irreversible) inhibitor of CYP2C9, while being a reversible, yet 
time-dependent, inhibitor of CYP3A4. Then CYP3A4 activity would possibly regain 
quickly enough for leaving the metabolism of CYP3A4 substrates unimpaired. A third 
explanation for the discrepancy between in vitro and in vivo data is the high plasma 
protein binding of noscapine. Fang et al. assumed a protein binding of 65% [201], 
whereas other investigators have shown that noscapine is protein bound to a consider-
ably greater extent (85-93%)  [209].  
Fact remains: in vitro findings are not always readily applicable for in vivo conditions! 
 
5.4.2 Glucosamine 
We could also clearly show, that glucosamine does not affect the activity of either of 
the probed cytochrome P450s. Thus a metabolic interaction between glucosamine and 
warfarin can be ruled out. However, several case reports of high quality suggest that 
there is some kind of drug-drug interaction between these two substances. This is 
probably pharmacodynamic. We did not notice any direct anticoagulant effect of 
glucosamine in our study, as INR values were unchanged in our subjects. 
A pharmacodynamic interaction between glucosamine and warfarin may occur at any 
of several steps in the complex chain of events leading from inactive precursors to 
active vitamin-K dependent coagulation factors [139]. 
A potential pharmacokinetic interaction between glucosamine and warfarin that we 
have not addressed in our study is enhanced uptake. Glucosamine has been shown to 
enhance the bioavailability of tetracycline and during the late 1950’s and early 1960’s 
there was a combined preparation available called Cosa-Tetracyn® [134, 210]. The 
mechanism seems not to have been extensively elucidated, but since warfarin and 
tetracyclines are both weak acids [211], absorption may be enhanced by a weak base 
such as glucosamine. However, since warfarin is readily absorbed, whereas tetracycline 
has a lower and varying bioavailability of 60–80% [212], this mechanism is unlikely 
for the warfarin–glucosamine interaction. 
 
5.5 THE ANSWER 
The question in paragraph 1.1 cannot be answered with absolute certainty as we have 
not, yet, done a direct interaction study with noscapine and warfarin, but the evidence 
for an interaction is very strong: an increasing number of case reports, in vitro and in 
vivo findings that noscapine inhibits the key enzyme in warfarin metabolism. The in 
vitro findings have also been reproduced by an independent group and in a different test 
system than we used in Paper IV. 
The Swedish Medical Products Agency has taken regulatory action on the results in 
Paper V: noscapine is still available OTC, but it cannot be sold outside of 
pharmacies [213]. 
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6 FUTURE PERSPECTIVES 
6.1 CYP2C19*17 
There are preliminary data suggesting that oestrogens do not inhibit the expression of 
the CYP2C19*17 allele and CYP2C19*17 carriers may therefore not be inhibited by 
oral contraceptives as are CYP2C19 wild-type carriers. This would be interesting to 
confirm in a clinical trial. 
 
In the near future, we will also hear more about the role of CYP2C19 activity in 
clopidogrel resistance (both from the pharmacogenomics and the drug interaction 
perspective).  
 
The most important pharmacokinetic feature of CYP2C19*17 carriers may be their 
high and uniform CYP2C19 activity. It remains to determine the causes of the wide 
range of metabolic activity seen in individuals with CYP2C19 wild-type genotype. 
 
6.2 NOSCAPINE 
We are currently performing a direct interaction study with noscapine in stable main-
tenance warfarin treated patients. We give noscapine 50 mg t.i.d. for a maximum of ten 
days. The patients are sampled every day and noscapine is withdrawn if the INR 
reaches a prespecified level. 
 
It would also be interesting to do a study of how the pharmacokinetics and pharmaco-
dynamics of oral antidiabetics are affected when co-administered with noscapine. Such 
a study could be done in a fashion similar to the cocktail study of Paper V. 
Pharmacodynamics could be monitored by the glucose–insulin clamp technique or, 
simpler, by measuring plasma glucose and insulin during an oral glucose tolerance test. 
It could also be done under steady-state conditions in stable patients with diabetes type 
2. 
 
The impact (or lack of impact) of noscapine on in vivo CYP3A4 activity could also be 
worth further investigation with other measures of CYP3A4 activity. 
 
6.3 GLUCOSAMINE 
It would be interesting to design and perform a clinical trial to try to elucidate the 
mechanism of the potential drug–drug interaction between glucosamine and warfarin. 
Such a trial would probably need to be performed in patients on stable maintenance 
warfarin, as warfarin pharmacodynamics may be difficult to study after single doses in 
healthy volunteers. 
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